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Abstract 
 
This dissertation thesis consists of a series of chapters that are interwoven by 
solving interesting biological problems, employing various computational methodologies. 
These techniques provide meaningful physical insights to promote the scientific fields of 
interest. Focus of chapter 1 concerns, the importance of computational tools like docking 
studies in advancing structure based drug design processes.  This chapter also addresses 
the prime concerns like scoring functions, sampling algorithms and flexible docking 
studies that hamper the docking successes. Information about the different kinds of 
flexible dockings in terms of accuracy, time limitations and success studies are presented. 
Later the importance of Induced fit docking studies was explained in comparison to 
traditional MD simulations to predict the absolute binding modes.  
Chapter 2 and 3 focuses on understanding, how sickle cell disease progresses 
through the production of sickled hemoglobin and its effects on sickle cell patients.  And 
how, hydroxyurea, the only FDA approved treatment of sickle cell disease acts to subside 
sickle cell effects. It is believed the primary mechanism of action is associated with the 
pharmacological elevation of nitric oxide in the blood, however, the exact details of this 
mechanism is still unclear. HU interacts with oxy and deoxyHb resulting in slow NO 
production rates. However, this did not correlate with the observed increase of NO 
concentrations in patients undergoing HU therapy. The discrepancy can be attributed to 
the interaction of HU competing with other heme based enzymes such as catalase and 
 ix 
 
peroxidases. In these two chapters, we investigate the atomic level details of this process 
using a combination of flexible-ligand / flexible-receptor virtual screening (i.e. induced 
fit docking, IFD) coupled with energetic analysis that decomposes interaction energies at 
the atomic level. Using these tools we were able to elucidate the previously unknown 
substrate binding modes of a series of hydroxyurea analogs to human hemoglobin, 
catalase and the concomitant structural changes of the enzymes. Our results are consistent 
with kinetic and EPR measurements of hydroxyurea-hemoglobin reactions and a full 
mechanism is proposed that offers new insights into possibly improving substrate binding 
and/or reactivity.  
Finally in chapter 4, we have developed a 3D bioactive structure of O
6
-
alkylguanine-DNA alkyltransferase (AGT), a DNA repair protein using Monte Carlo 
conformational search process. It is known that AGT prevents DNA damage, mutations 
and apoptosis arising from alkylated guanines.  Various Benzyl guanine analouges of O
6
- 
methylguanine were tested for activity as potential inhibitors. The nature and position of 
the substitutions methyl and aminomethyl profoundly affected their activity. Molecular 
modeling of their interactions with alkyltransferase provided a molecular explanation for 
these results. The square of the correlation coefﬁcient (R2 ) obtained between E-model 
scores (obtained from GLIDE XP/QPLD docking calculations) vs log(ED)values via a 
linear regression analysis was 0.96. The models indicate that the ortho-substitution causes 
a steric clash interfering with binding, whereas the meta-aminomethyl substitution allows 
an interaction of the amino group to generate an additional hydrogen bond with the 
protein.  Using this model for virtually screening studies resulted in identification of 
 x 
 
seven lead compounds with novel scaffolds from National Cancer Institute Diversity 
Set2.
 1 
 
 
 
Chapter 1. In silco Structure Based Molecular Modeling 
Incorporating Receptor Flexibility 
1.1 Structure based drug design 
The central goal of drug discovery involves lead optimization of small molecules 
that favorably regulates the enzymes biological activity. Most pharmaceutical companies 
use wet-lab based high throughput screening (HTS) for detection of novel lead 
compounds. However, these drug development processes are time consuming, expensive, 
and have low hit rates, which led to the development of cost effective in-silico type 
structure based drug designing techniques.
1
  Structure based drug design (SBDD) 
techniques rely on a high resolution 3D bioactive protein structures obtained through 
experimental techniques like X-ray crystallography or NMR. Alternatively, 
computational homology modeling can create these if experimental 3D structures are not 
available. Subsequently, various small molecule libraries are virtually screened in protein 
active-site and the approximate binding affinities are estimated with the help of in silico 
drug design tools such as docking programs. Further, low-energy compounds with good 
complementary interactions are screened based on visual inspection, virtual ADME 
calculations, and Lipinski’s rule of five. Following this procedure, the top scoring 
compounds are produced from chemical vendors or synthesized in the laboratory for 
biological testing.
2
 Once the lead compound is identified, structure activity relationship 
(SAR) studies are performed to improve the biological activity of the lead compound. 
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Finally, the whole SBDD process is reiterated but focused libraries similar to the lead 
compound are used with advanced docking tools to best obtain the ideal drug candidate.  
1.2 Molecular docking studies 
Docking studies play a critical role in the development of novel drugs with unique 
molecular scaffolds in SBDD efforts including virtual screening studies. For over 20 
years
3
 docking studies have been primarily used for predicting correct binding poses and 
estimating approximate binding affinities by scoring interaction energies between the 
protein x-ray crystal structure and small molecules of interest. Initial docking studies 
were based on the lock and key theory proposed by Emil Fischer,
4
 in which the ligands 
are bound to a protein receptor in a lock and key fashion. This docking protocol treats 
both the ligand and receptor as rigid bodies, however current developments include 
ligand flexibility in programs such as Glide,
5
 GOLD,
6
 AutoDock,
7
 and FlexX.
8
 The 
primary goals of docking studies are predicting experimental binding modes, identifying 
false positives from true binders and predicting absolute binding free energies for a given 
ligand library. However, despite the development of over 60 docking programs
9
 the 
attempts to use a universal docking program to satisfy these goals are difficult. These 
limitations arise due to various factors like approximations used in docking programs, 
inadequate sampling of ligand degrees of freedom, validation of docking programs using 
only limited protein-ligand data sets,  not accounting for protein flexibility, and scoring 
function issues in handling metals, co-factors, covalent interactions, explicit water 
molecules etc.
3
 However, addressing limitations such as scoring function, sampling 
algorithms, and receptor flexibilities remain active areas of research.  
 3 
 
  
Figure 1-1: Flowchart displaying the prime concerns consisting of ligand sampling, 
scoring function, and flexible docking studies. 
1.3 Scoring Functions 
One of the primary objectives of a scoring function is to estimate the relative 
binding energies of small molecules to the protein active site and rank their putative 
binding affinities. One scoring function limitation is the ineffectiveness to predict 
absolute binding free energies due to simplification and approximations to save on 
computational time. Development of scoring functions remains an active area of research 
to increase accuracy, namely to discriminate true binders from false positives in virtual 
screening studies. Scoring functions are classified into four basic schemes which are 
Force field, Empirical, Knowledge, and Consensus based scoring functions. 
1.3.1 Force field based scoring functions:  Force field based scoring functions (FFSF) 
rely upon molecular mechanics type methods that are fundamentally used to calculate the 
intermolecular interactions such as bonds, angles, improper torsions, dihedrals and 
intramolecular/intermolecular non-bonded interactions like van der Waals, electrostatics, 
and ligand strain energies.
10
 Most of the current FFSF are simplified by neglecting 
protein internal energy calculations but may include ligand strain energies induced upon 
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ligand binding to the protein. Generally, electrostatic terms are accounted by Columbic 
potential using a distance dependent dielectric function. The van der Waal terms are 
governed by a Lennard-Jones potential that controls both repulsive close contacts 
sometimes referred to as “hardness” of intermolecular forces and long range attractive 
forces. The standard FFSF, have certain limitations like high computational cost, and lack 
of solvation and entropy terms. Moreover, the long range non-bonding interactions 
cannot be treated accurately due to the arbitrary selection of cut-off distances.
11
 However, 
the current progress in FFSF include: hydrogen bonding interactions, solvation, and 
torsional entropy terms. And some examples of docking programs that use FFSF are 
GOLD
6
 and Autodock.
7
 Recent developments include solvation incorporate treating 
water as a continuum dielectric medium.
10
 Poisson-Boltzmann/Surface Area (PB/SA) and 
Generalized Born/Surface Area (GB/SA) are the common examples of implicit solvent 
models recently included in the DOCK program.
12
 
1.3.2 Empirical scoring function: The empirical scoring function is parameterized using 
experimental binding free energies that consist of the sum of weighted interaction energy 
terms. The weighing factor or the co-efficient of various energy terms are obtained by  
regression analysis of experimentally available binding energies and binding geometries 
from molecular training sets of 3D protein bioactive structures.
13,14
 Empirical scoring 
functions (EF) are very similar to FFSF’s, however, they include additional interaction 
energy terms like hydrophobic, hydrogen bonding, entropy, ligand strain, metal-ligation 
and π-π stacking interactions. Popular empirical scoring functions are ChemScore, Glide, 
and LUDI.
5,15,16
 Empirical scoring functions are limited in accuracy due to limited 
 5 
 
training sets used and it is unclear how well it is suited to model intermolecular forces 
across the proteome.  
1.3.3 Knowledge based scoring function: The knowledge based pair-wise potentials 
(KSF) are generated using the reverse Boltzmann potential construction method.
17
 This 
employs the statistical analysis of pairwise atomic interactions using experimental 3D 
bioactive structures. The scoring functions are built on the assumption that the stronger 
the complementary interactions, the more likely their statistical occurrence would be. 
Based on this statistical analysis the knowledge based scoring functions scores favorable 
contacts and penalizes low statistical occurrences from biomolecular interatomic forces.  
These KSF can do an excellent job in modeling binding contributions such as solvent 
effects, conformational entropy, interaction enthalpy,
17
 and rare interactions like cation-π 
and sulphur-aromatic interactions that remain a challenge for classical force fields.
11
 
However, like ESFs even the KSFs are limited in accuracy due to limited 
parameterization resulting from small training sets of 3D bioactive structures. Moreover, 
KSFs have problems dealing with metals and halogens. Some common examples of 
KSFs used in docking methods are SMoG,
18
  PMF,
19
 Gold/ASP,
20
 and Kscore.
21
  
1.3.4 Consensus scoring function: Imperfections of other scoring functions in terms of 
accuracy and aspirations for a universal scoring function have lead researchers to develop 
consensus scoring functions (CSF). In order to maximize advantages and minimize 
deficiencies, CSF combines information from different scoring functions. Moreover, the 
CFS’s primary objective is to improve the enrichments in virtual screening studies to 
identify the true binders from false positives. However, CFSs often can underestimate the 
binding affinities if it is built upon a combination of highly correlated scoring functions. 
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Various CFSs include MultiScore,
22
 X-Cscore,
23
 Cscore
24
 etc. are used in current docking 
programs. The popular CFS X-Cscore combines scoring functions of Gold, Dock, 
ChemScore, PMF and FlexX.
25
   
1.4 Sampling Algorithms 
Ligand sampling is one of the most important prerequisites for successful 
application in docking studies by searching all possible ligand degrees of freedom to 
capture the experimental binding orientation. Sampling algorithms need to be robust 
enough to generate all putative ligand orientations to capture the experimentally solved 
binding modes in the protein active-site. Presently, the docking programs employ ligand 
sampling by two possible strategies: whole molecule and fragment based sampling 
approaches. The majority of sampling methods use the whole molecule approach to 
sample the pose space. Further, whole molecule methods produce pre-calculated ligand 
conformations by Monte Carlo (MC), Molecular Dynamic simulations (MD), Genetic 
algorithms (GA), and simulated annealing (SA) techniques.   
1.4.1 Monte Carlo Conformational Search: MC based algorithm searches the ligand 
conformational space through random torsional sampling of rotatable bonds. These new 
sets of conformations are generated by satisfying an energy based criterion after initial 
perturbations. This method is superior to MD in exploration of search space by crossing 
the high energy barriers on the potential energy landscape. Many docking programs like 
Glide,
5
 Rosetta Ligand,
26
 and ICM
27
 employ MC sampling for generating pre-determined 
ligand conformations.  
 7 
 
1.4.2 Genetic Algorithms: The underlying theory of these methods comes from Charles 
Darwin theory of evolution. The ligand translational, rotational, and torsional degrees of 
freedom are treated as genes with corresponding energies. The mutation of this gene 
generates a new pose based on an energy fitness scheme. The exploration of the complete 
genome would give us the potential energy landscape along with the global energy 
minimum of the ligand pose. Many docking programs employ genetic algorithms for 
ligand sampling inclusing GOLD,
6
 DIVALI,
28
 and  AutoDock.
7,29
  
1.4.3 Simulated Annealing: These methods allow the exploration of the global minimum 
by escaping the local minima via crossing local energy barriers through a temperature 
controlled Metropolis criterion algorithm. This method involves heating the ligand to a 
high temperature and cooling it slowly to obtain the preferred conformational states of 
the ligand.  This is a stochastic algorithm as a random population of ligand conformations 
are produced in different attempts, in spite of the exact cooling conditions. Earlier 
versions of AutoDock
7,29
 used the simulated annealing approach.  
1.4.4 Fragment based Ligand Sampling: This method entails dissecting the ligand 
molecule into several fragments: a base fragment and flexible fragments. The base 
fragment is docked first in optimal orientation to establish favorable complementary 
interactions. Later, the incremental reconstruction of flexible fragments is undertaken in a 
stepwise manner to explore all possible bond rotational search space that confers ligand 
elasticity.  Moreover, unreasonable conformations are discarded at the early stage using a 
pruning algorithm to save on computational time.
25
 This method can further be extended 
to de novo design programs by constructing newer ligands by altering the bond 
connectivity of the parent ligand using incremental construction algorithms.
14
 Various 
 8 
 
docking programs like FlexX,
8
 Hammerhead,
30
 and DOCK
12
 use fragment based ligand 
sampling methods.  
1.5 Limitations 
Despite recent developments in scoring functions and ligand sampling algorithms, 
several challenges still exist with rigid docking strategies. One such limitation would be, 
ligand size greater than ten rotatable bonds, which poses a greater challenge to obtain the 
correct ligand conformation. Likewise, exhaustive ligand sampling protocols, in an 
attempt to capture the true binding mode can sometimes lead to unnecessary 
conformational exploration that drains computational resources. Further, it was shown 
that rigid receptor dockings cannot reproduce experimental binding modes for 50-70 % of 
the ligand docking studies.
31
 Many cross docking experiments have shown that the 
docking accuracy drops when an alternative protein conformation is used other than the 
true protein conformation. Abagyan and co-workers used a set of 33 protein kinases in 
cross docking studies and found a decrease in docking accuracy by 30%.
32
  Hence current 
research is focused on developing methods that evaluate protein degrees of freedom 
along with ligand sampling to solve the flexibility issues for predicting correct 
experimental binding modes.  
1.6 Flexible docking studies 
David Koshland was the first to expand upon the flexible protein – flexible ligand 
initiative by introducing the induced fit theory.
4
  Additionally, it has become evident that 
proteins in the biological systems undergo dynamic motions ranging from bond 
vibrations, torsional rotations, hinge bending, loop refinements, allosteric regulations, and  
large scale domain motions.
31
 Further, the plethora of available 3D X-ray and NMR 
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structures indicates that protein flexibility results from intrinsic disorder or from ligand 
induced adaptions. Many of these dynamic forces influence binding orientations of small 
molecule ligands by forming various complementary interactions due to protein 
flexibility.  Hence, many flexible docking methods have been developed to confer protein 
degrees of freedom under three main categories: soft docking, side-chain sampling or full 
protein flexibility.   
 
Figure 1-2: Flowchart describing the different types of flexible receptor docking 
approaches. 
1.6.1 Soft docking studies 
A previous attempt to include protein plasticity in rigid docking studies was 
derived from soft potentials allowing a certain degree of steric fitting between the ligand 
and the protein binding site. Jiang et. al, were the first to explore the soft docking 
approaches in order to augment the complementary interactions between a protein-ligand 
complex, otherwise not possible with apo crystal structures.
33
 They developed a 
molecular docking protocol using a cube representation describing molecular surface and 
volume. Geometric docking they used is based on the shape and size structural 
complementarity between protein-ligand interface using soft potentials that generates an 
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ensemble of structures. Later they screened and filtered these complexes based on 
favorable energy cutoffs to get subpopulations of these complexes. They applied this 
method using trypsin complexed with a trypsin inhibitor using PDB: 2PTC and redocked 
random orientations and obtained experimental binding modes. Recent strategies for soft 
docking methods involve manipulating the scoring function.  The modification of 
repulsive van der Waals interactions of the protein-ligand complex is performed by 
replacing the Lennard-Jones 12-6 potentials with 9-6 potentials.
34
 Docking programs like 
GOLD
6
 uses the Lennard Jones 8-4 potentials and AutoDock
29
 uses smooth potentials in 
their soft docking approaches. Soft docking studies are computationally efficient and fast 
as they take the same amount of time as rigid docking studies. Using these soft potentials, 
Ferrari et al. screened the Available Chemical Directory (ACD) small molecules to the 
T4 lysozome which resulted in better enrichments compared to hard potential based 
docking.
34
 They found that docking to multiple receptor conformations of aldose 
reductase led to the production of 6 inhibitors, which are poorly scored in their soft 
docking approach.  Likewise, they had limited success due to minor side-chain movement 
and eventually steered the development to other semi-flexible methods. 
1.6.2 Semi-flexible docking studies 
Semi-flexible docking methods generate specific degrees of freedom by dynamic 
sampling of side-chains keeping the backbone fixed during the simulations. Leach
35
 
introduced earlier methods for incorporating side-chain sampling by generating discrete 
low energy intermolecular protein conformations using rotamer libraries. At around the 
same time, Abagyan et al. developed the internal coordinate method (ICM) that samples 
receptor side chains using a Brownian Monte Carlo minimization, which includes 
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solvation and surface tension in the internal coordinates space of the protein complex.
27,36
 
They used the GCN4 transcriptional activator PDB X-ray crystal structure to dock 
flexible Leucine zipper helices of 31 residues and obtained strong intermolecular parallel 
helices with a root mean square deviation of 1.18 Å from the experimentally derived 
structure. Recently, Dean and co-workers
37
 used random side chain torsional angles χ 
instead of rotamer libraries to incorporate receptor side-chain flexibilies in their docking 
program SkelGen. They employed a SA protocol to sample side-chains during ligand 
docking to the active-sites of acetylcholinesterase and matrix metalloproteinase-1 and 
concluded its safe to use random torsional angles without using rotamer libraries.  Other 
popular docking programs that use flexible side-chain protocols are AutoDock 4,
38
 and 
FDS.
39
 
1.6.3 Fully flexible docking studies 
For highly flexible receptor sites, current computational techniques can induce 
full flexibility of protein-ligand interactions by three ways: ensemble docking, induced-fit 
docking and mutual adaptive coupled interaction studies. These tools are classified based 
on the characteristic differences of whether the ligand binds before, after or during the 
protein conformational changes.  If the ligand chooses the pre-existing ligand bound-
protein conformational states then it is classified as ensemble dockings. However, if 
protein structural changes are induced upon ligand binding then induced-fit docking is 
used. Finally, protein-ligand conformational changes happen simultaneously, mutual 
adaptive coupled interactions studies are used to explore the protein-ligand 
conformational degrees of freedom concurrently.  
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1.6.4 Ensemble docking studies 
Proteins are dynamic entities existing in a diverse set of conformational states 
populated in dynamic equilibrium. Many researchers believe that ligands undergo 
“conformational selection” process from a collection of pre-existing ligand bound 
states.
4,40
 Moreover, Boehr et al.
4
 proposed that ligands generally bind weakly populated 
high energy receptor conformations to undergo an ensemble redistribution via population 
shift leading to a net gain in free energy. Hence, the first step in traditional ensemble 
docking constitutes the generation of ensemble receptor structures using any one of the 
following techniques: MD simulations, Monte Carlo conformational search, normal mode 
analysis and Simulated Annealing followed by sequential flexible ligand docking.   
The high computational cost associated with traditional ensemble docking lead to 
the development of hybrid ensemble docking techniques like 4D docking,
41
 FlexE,
42
 and 
DOCK.
43
 The 4D docking protocol developed by Abagyan and co-workers
41
 is much 
faster than traditional ensemble docking studies and their method reproduced 
experimental binding modes in 77.3% of their test cases. Their 4D docking describes 
protein flexibility as a 4
th
 dimension relative to the ligand 3D space. Several 3D grids of 
the receptors from the ensemble have been recomputed into a single 4D object (set of 4D 
planes that describes the different protein conformations) using a superposition 
algorithm. The implementation of a Monte Carlo sampling protocol, indicates that ligand 
conformational changes are brought about in terms of torsional, rotational, and 
translational movements from one 4D plane to another. Finally, all the poses within 1 
kcal/mol of the lowest energy pose were retained for further analysis. Another advanced 
program like FlexE
42
 uses a slight variation to 4D docking, in which the program 
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combines multiple structure receptors, merging the rigid parts, and identifying the 
flexible parts as dissimilar receptor conformations. During the incremental construction 
of ligand, the ligand was sampled against various protein conformations to have the 
maximum complementary interactions with flexible parts followed by score and rank.  
1.6.5 Induced fit docking studies 
Dissimilar from the lock and key theory, in induced fit theory ligand binds to the 
receptor conformation by reshaping its active-site conforming to the ligand shape. This 
process enhances the complementary interactions like electrostatics, van der Waals, 
hydrogen bonding etc. It was recently shown that 85% of the PDB structures contain one 
to three flexible active-site residues
44
 showing the high probability of induced fit effects. 
Hence some of the popular programs like Induced fit docking (IFD) protocol
45,46
 using 
Glide/Prime would allow the users to select residues that are flexible based on B-factors 
or based on RMSD’s from experimentally available structures. The Fleksy program47 
identifies the residues automatically based on certain rules or the user can select them 
manually.  Most of the current docking schemes account for the induced fit effects using 
a hybrid scheme. The processes generally include using softened potentials and 
performing side chain sampling using rotamer libraries to include protein plasticity. 
Further, these ligand conformations are docked into multiple receptor structures to 
generate an ensemble of protein-ligand complexes. Later, these suboptimal poses undergo 
partial refinement followed by redocking and final scoring of their respective binding 
energies. The popular Prime/Glide IFD method is a hybrid model that is a flexible 
receptor – flexible ligand docking protocol which accurately predicts the binding modes 
by iterative combination of rigid docking (Glide)
5
 with protein structure prediction 
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technique (Prime)
48,49
 to produce induced fit effects. IFD is computationally efficient, as 
it performs side chain sampling in dihedral angle space while allowing minor backbone 
movements through Prime energy minimization conferring full protein flexibility. This 
technique is ideal for X-ray structures with no bound ligand (apo structure), in which the 
amino acid residues protrude into the active-site leaving a closed active-site conformation 
and causing rigid dockings to fail. The robustness and accuracy of the IFD methodology 
has been originally validated on 21 pharmaceutically relevant protein targets by cross 
docking studies.
46
 The IFD protocol successfully generated binding modes with ligand 
RMSD ≤ 1.8 Å for 18 of the 21 test cases.  Furthermore, the 21 test cases have an average 
ligand RMSD of 1.4 Å when docked to the flexible receptors, while the traditional rigid 
receptor docking gave an average RMSD of 5.5 Å.   
SCARE
50
 is a similar induced fit docking program that scans for adjacent side-
chains and replaces them with alanines creating a gapped pocket to reduce steric 
hindrance, which is caused by docking bulky ligands into the active-site. Next, back 
mutation of alanine paired residues to original residues is performed. Followed by 
refinement and rescoring the ligands obtained a near native conformation (< 2Å RMSD) 
for 80% of adjacent pairs using this method.  Recently, an alternative CHARMM force-
field based IFD method was developed, that uses a similar multi stage induced-fit 
docking process.
51
 The ChiFlex program was employed in the multi stage process to 
sample the side chain conformations using a ChiRotor algorithm
52
 by selectively 
removing less than 10 residues to create a gapped active-site pocket to generate an 
ensemble of complexes. Later in the protocol, the favorable intermolecular forces are 
maximized by identifying a hot spot for the ligand placement. CHARMM energy 
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minimization calculations were performed to remove steric clashes resulting from side 
chain reconstruction. And CHARMM based CDOCKER
53
 docking application is 
employed to sample the ligand conformations using high temperature MD simulations 
inside of the rigid receptor active-site to obtain the final intermolecular complexes. This 
IFD method using 21 test cases obtained an RMSD < 2Å within the top five hits except 
for one case.  
1.6.6 Mutual adaptive coupled interaction studies 
Accurate prediction of the dynamic nature of biological protein-ligand 
interactions includes the understanding of simultaneous coupled forces between the 
binding partners. This ultimately captures its snapshots of highly populated stable 
conformations that represent true experimental stable structures. In addition, considering 
only coupled interactions would restrict conformational degrees of freedom to relevant 
binding conformations saving a lot of computational time.  The ROSETTALIGAND
26,54
 
is a popular docking method that simultaneously optimizes receptor side-chain, backbone 
along with ligand flexibility degrees of freedom. This docking protocol models the 
coupled interactions by using a Monte Carlo minimization procedure, where each ligand 
from an ensemble of ligand conformations is translated and rotated along with 
simultaneous optimization of receptor side-chains. The ligands are first placed effectively 
in the active-site, based on shape complementary search. The side-chain optimization 
starts with substitution of side-chains with rotamers from a backbone dependent rotamer 
library,
55
 followed by quasi-Newton minimization.  The end results are accepted based on 
a Metropolis Criterion followed by a stringent gradient based minimization accounting 
for ligand sampling along with receptor side-chain torsions and backbone flexibility. The 
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first version of ROSETTALIGAND itself was reasonably good, a correlation co-efficient 
of 0.63 was obtained when comparing between predicted binding energies to 
experimental binding energies using a diverse set of 229 protein-ligand complexes.
26
 
Moreover, the recent version of ROSSETTALIGAND was used to find the top scoring 
ligand poses with  RMSD < 2Å  for 54/85 cases.
54
 
Another traditional technique for capturing the coupled interactions of the protein-
ligand forces consists of MD simulations. MD simulation allows the biomolecular system 
to evolve over time and are described by using Newton’s equation of motion. The 
velocities and positions are tracked as a function of time to get the respective kinetic 
energy and potential energy of the system. MD simulation aids in determining ensemble 
averages and predicts ground state conformations of the protein-ligand complexes. Four 
steps are involved in regular MD simulations, initializing the system with a specific 
velocity and positions. Newtons equation of motion is used to compute the forces acting 
on the system to determine its new positions. The system would reach equilibrium losing 
the memory of initial conditions. The thermodynamic averages are calculated for 
quantities of interest. Once the protein-ligand system is well equilibrated, the trajectory of 
phase space should sample the regions of high probability distributed according to the 
Botlzmann distribution. However, the small time steps in MD simulations prevent the 
crossing of high energy barriers on potential energy surface (PES) causing inadequate 
sampling. Further, despite the development of explicit solvent MD simulations for 
binding mode predictions, success remains limited due to slow kinetics that form the 
correct protein-ligand complexes (possibly needs few microseconds or longer 
simulations) due to insufficient time to perform side-chain sampling and cross high 
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energy barriers. Guida and co-workers
56
 have suggested that flexible ligand docking into 
flexible active-site cannot be effectively performed using MD simulations due to large 
energy barriers associated with ligand translational and rotational movements in the 
PNP/9-deaza- 9-benzylguanine complex and have utilized torsional MC and low 
frequency normal modes to account for protein side chain flexibility.
57
  
1.7 Conclusion 
A plethora of docking strategies exists that incorporate protein flexibilities in 
ligand docking and are discussed in several review articles.
3,11,25,40,58-60
 A short overview 
has been given for the currently existing flexible receptor docking protocols along with 
their successful applications.  Despite the successful development of flexible docking 
protocols, a universal docking program that correctly predicts binding modes and 
accurately rank orders binding affinities doesn’t exist. Every receptor target is unique 
displaying various conformational degrees of freedom, ranging from bond vibration to 
large scale domain motion. Hence, understanding the target receptor flexibility is of 
prime importance to employ the correct flexible docking strategy ranging from moderate 
plasticity like soft docking to fully flexible mutual adaptive interactions. Moreover, the 
rigid docking programs in general are fairly accurate in predicting the binding affinities 
for a congeneric series of ligands. In addition, the availability of structural information 
for various potential inhibitors can help design hit molecules (SAR studies) by predicting 
the binding modes and understanding their possible molecular interactions with the 
receptor.  For our research studies in chapter 2, and 3 we used Schrodinger’s IFD 
protocol that uses a combination of the Glide and Prime program. Glide has been well 
validated
49,50
 while Glide / Prime has been shown to outperform other rigid and flexible 
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receptor docking protocols.
61
 This technique is ideal for X-ray structures with no bound 
ligand (apo structure). In such cases, amino acid side chains often protrude into the 
active-site restricting conformational space, resulting in the failure of rigid docking 
methods. Alternative approaches for incorporating flexible receptors into ligand docking 
protocols exist; however, common procedures like explicit solvent MD simulations have 
experienced limited success in predicting protein-ligand complexes.
46
 This limitation 
results from several factors with two aspects particularly problematic. The first is the 
necessity for accurate small molecule force fields.
62-64
 This is an active area of research, 
but presently there is no comprehensive solution. A second problem exists if significant 
active site reorganization is required for ligand binding. In this case, extensive 
simulations (up to microseconds) may be required to cross the high energy barriers of 
side-chain and/or backbone rearrangement. In contrast, IFD incorporates both side-chain, 
and to some extent backbone flexibility in a more computationally efficient manner. This 
has been extremely useful for a wide variety of computational biology studies.
65-70
 For 
example, Celik et al.
66
 showed that IFD was able to prospectively predict the binding 
mode of ligand neurotransmitter serotonin (5-HT) to the human serotonin transporter 
(hSERT).  Additionally, Barreca et al.
71
 predicted the binding mode and mechanism of 
action of integrase strand transfer inhibitors in the target HIV-1 integrase.  Hence, we 
utilized this protocol in most of our research projects using a customized induced fit 
docking (IFD) procedure to determine the binding modes of a series of HUA’s in both 
hemoglobin and catalase Enzymes described below. 
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Chapter 2. Unlocking the Binding and Reaction Mechanism of 
Hydroxyurea Substrates as Biological Nitric Oxide Donors.   
Note to the Reader 
This chapter has been published as Vankayala, S. L.; Hargis, J. C.; Woodcock, H. 
L.  Unlocking the Binding and Reaction Mechanism of Hydroxyurea Substrates as 
Biological Nitric Oxide Donors,  J. Chem. Inf. Model. 2012, 52, 1288-1297. Copyright © 
2013 American Chemical Society.  doi: 10.1021/ci300035c.   PMID: 22519847 
Author contributions. SLV and HLW designed the research; SLV performed research, 
analyzed data and wrote the initial draft; HLW and JCH improvised the draft. 
2.1 Abstract 
Hydroxyurea is the only FDA approved treatment of sickle cell disease. It is 
believed the primary mechanism of action is associated with the pharmacological 
elevation of nitric oxide in the blood; however, the exact details of this are still unclear. 
In the current work, we investigate the atomic level details of this process using a 
combination of flexible-ligand / flexible-receptor virtual screening coupled with energetic 
analysis that decomposes interaction energies. Utilizing these methods we were able to 
elucidate the previously unknown substrate binding modes of a series of hydroxyurea 
analogs to hemoglobin and the concomitant structural changes of the enzyme. We 
identify a backbone carbonyl that forms a hydrogen bond with bound substrates. Our 
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results are consistent with kinetic and EPR measurements of hydroxyurea-hemoglobin 
reactions and a full mechanism is proposed that offers new insights into possibly 
improving substrate binding and/or reactivity. 
2.2 Introduction 
Sickle cell disease (SCD) is an autosomal recessive disorder resulting from the 
mutation of the 6
th
 amino acid in the -globin gene changing from polar glutamic acid to 
non-polar valine.
72-74
 Two biomedically relevant phenotypes of hemoglobin expressed are 
normal adult hemoglobin (HbA) and its mutated SCD equivalent (HbS). More 
specifically, upon deoxygenation mutated hemoglobin undergoes a conformational 
change resulting in formation of long fiber-like polymers. Polymerization of HbS inside 
of red blood cells distorts them into crescent shapes (i.e. sickled). Further, sickling causes 
the extracellular exposure of protein epitopes and glycolipids that are normally found 
inside the cell. Improperly exposed cellular components lead to increased adhesion of 
sickled red blood resulting in stroke, acute organ damage, and death.
75-77
  
Two current treatment options for SCD are administration of hydroxyurea (HU) 
or red blood cell replacement.
78,79
 Hydroxyurea, the only FDA approved treatment for 
SCD, involves the pharmacological elevation of nitric oxide (NO) and induction of fetal 
hemoglobin (HbF).
80
 Watson et al. found that HbF ameliorates sickle cell severity.
81
 HbF 
is primarily present in infants as an oxygen carrier protein during the last 7 months of 
gestation through the first six months of a newborn’s life.82 HbF is a tetramer consisting 
of two α and two γ globins (α2γ2), which accounts for approximately 1% of hemoglobin 
in adults. HbF combines with oxygen more easily than adult hemoglobin due to the γ 
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subunits that have more remote negative charge than its adult β counterpart.73 In SCD 
patients, raising HbF levels lowers the cellular concentration of HbS and results in less 
polymerization hence lower incidence of sickled red blood cells. HbF also serves as a 
prognostic factor for sickle cell complications and pain crises.
83
 Although millions of 
people have received this treatment, the detailed mechanism of action remains elusive. 
It is thought that NO plays a key role in SCD treatment by producing smooth 
muscle relaxation, vasodilation, and increasing regional blood flow to help prevent cell 
adhesion to endothelial cells.
84
 Further, NO released from the endothelium activates the 
NO/cGMP pathway
85
 that regulates expression of the γ globin gene along with 
stimulation of HbF synthesis. During hydroxyurea administration, elevated levels of NO 
metabolites, cGMP, and HbF are observed.
86-88
 Intrigued by in vivo conversion of 
hydroxyurea to NO along with induction of HbF, research has focused on substrate 
interaction with heme based proteins that catalyze redox processes. For example, Oxy-
Hemoglobin (OxyHb), Deoxy-Hemoglobin (DeoxyHb) and Met-Hemoglobin (MetHb) 
have been shown to form Nitrosyl-Hemoglobin (HbNO), a source of NO.
73,88-90
 
The structure of HbA, a tetramer assembly consisting of two α globins and two β 
globins, has been studied extensively.
91-97
 Each of these subunits consists of a 
hydrophobic pocket that strongly binds the prosthetic heme group.
95
 The heme group is 
an octahedral coordinated system with ferrous iron having four coordinate bonds to 
porphyrin nitrogens and a covalent bond with the proximal histidine (His87) below the 
plane of the porphyrin ring. The sixth bond is a coordination bond with exogenous 
ligands such as oxygen, carbon monoxide, or nitric oxide inducing planarity of the heme. 
The immediate residues above the porphyrin ring plane constitute the distal pocket. 
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Oxygen binds to HbA in a complex cooperative mechanism where the oxygen association 
exhibits a sigmoidal curve.
98
 When OxyHb is auto-oxidized from the ferrous to ferric 
form it gives MetHb and superoxide
99
 with the sixth coordinate position of MetHb either 
empty or bound by a water molecule. In contrast, DeoxyHb is generated by 
deoxygenation of OxyHb leaving a ferrous state iron (Figure 2-1). 
 
 
 
 
 
Figure 2-1: Generic representation of various oxidation states of Iron that exist in human 
adult hemoglobin.  
 
In addition to its role in SCD therapy, hydroxyurea also acts as an S-phase 
specific chemotherapeutic agent used primarily to treat cancer. Therefore, cytotoxicity 
effects have been a major concern for patients undergoing treatment for SCD. This and 
additional properties have lead to trepidation amongst physicians about long-term SCD 
treatment with hydroxyurea,
74
 making the development of alternatives essential. In 2003, 
King and co-workers
88
 designed a series of hydroxyurea analogs (HUA) depicted in 
Figure 2-2 and examined their structure activity relationship using kinetic and EPR 
spectroscopic techniques. 
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Figure 2-2:  List of hydroxyurea analogs tested by King and co-workers from their 
structure activity relationship study.
17
 Defining various hydrogen atom representations: 
A. hydrogen bonded to the non-hydroxyl nitrogen atom (HN′) B. hydrogen bonded to 
hydroxyl nitrogen (HN) C. substituent groups bonded to the non-hydroxyl nitrogen atom 
(X) D. hydroxyl hydrogen (HO) Hydroxyurea (1) serves as the archetype showing HN´, 
HN, HO and X. 
Rate constants for the reaction of OxyHb and hydroxyurea analogs forming 
hydroxyurea nitroxide (HU-nitroxide) radicals have been previously determined.
88,89
 In 
that work, a reaction rate increase of 25-80 times was observed for N-hydroxyurea 
analogs compared to HU and it was suggested these would be superior nitric oxide 
donors. King and co-workers
88,90,100,101
 conducted several spectroscopic studies and 
proposed the mechanisms depicted in a series of redox reactions (Figure 2-3). These 
illustrate hydroxyurea’s interaction with hemoglobin to produce NO. The in vitro reaction 
of all hydroxyurea analogs except 2 and 3 produced HU-nitroxide radicals with OxyHb 
through the abstraction of HO by bound oxygen (Ob) to form MetHb and hydrogen 
peroxide. Additionally, all hydroxyurea analogs except 2, 3, and 7 were found to 
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coordinate with MetHb to form the MetHb-HUA complex. The complexes eventually 
decompose to form HU-nitroxide radical (2) analogs and DeoxyHb. Finally, NO is 
formed by the decomposition of 2 and combines with DeoxyHb to form nitrosyl 
hemoglobin (HbNO).
102
 The study concluded that effective NO release from hydroxyurea 
analogs requires the formation of a low spin MetHb-HU complex. They concluded this 
complex could only be formed if the necessary structural features were present: an 
unsubstituted −NHOH group and a HN´ atom, henceforth analogs 2, 3, 4 and 7 could not 
generate NO. They reasoned the HN´ requirement was steric in nature with the two ethyl 
groups bonded to N responsible for analog 7’s inability to form the low spin MetHb-
HUA complex.
88
  
Figure 2-3: Generic reaction scheme presented by King and co-workers.
17
 
MetHb 
MetHb MetHb-HU complex DeoxyHb 
MetHb 
OxyHb 
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However, the role of HN´ in the complex formation was not addressed due to 
unavailable structural information of hemoglobin with bound substrates. Moreover, there 
was no discussion or comparison of the active sites of OxyHb and MetHb.  
In the current work we utilize a customized induced fit docking (IFD) procedure 
to determine the binding modes of a series of HUA’s in both OxyHb and MetHb. The 
IFD
45,46
 protocol involves sampling dramatic side chain motions and minor backbone 
movement to predict OxyHb-HUA and MetHb-HUA complex structures starting from the 
apo conformation of OxyHb. Docking score decomposition analysis (i.e. Glide XP 
descriptor) is used to probe the intermolecular interactions that govern binding and 
stability. Sequence alignment and binding site similarity studies with α-HbA using 
ProBiS
103-105
 and ClustalW
106
 reveal several conserved active site residues. This 
information, in conjunction with available structural and biochemical data,
95,101,107
 is then 
used to propose detailed reaction mechanisms and suggest new strategies for the 
development of improved NO releasing substrates.  
2.3 Methods 
2.3.1 Protein and ligand/substrate preparation 
 X-ray crystal structure coordinates of apo OxyHb were obtained from the Protein 
Data Bank [PDB: 2DN1].
93
 2DN1 is a high resolution, 1.25 Å, dimer with a hydrogen 
bond between the distal histidine (His58) and Od, the distal oxygen atom (i.e. farther from 
the central iron of the oxy-heme moiety), of both the α and β-subunits.108 The α subunit 
was chosen because previous experimental and computational studies have shown it to 
have higher affinity for ligands than its β counterpart.109-111 The impact module of the 
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Schrödinger suite was used to predict the correct bond orders, add missing hydrogens, 
and remove the co-crystallized water and toluene solvent molecules. The HIE protonation 
state (protonated on N) was selected for His58 in OxyHb due to the aforementioned 
hydrogen bonding.
94,112,113
 Subsequently, a minimization (Truncated Newton Conjugate 
Gradient, TNCG) employing the OPLS-2005 force field with a constant dielectric of 2 
was performed freezing the oxy-heme, proximal histidine (His87),
107
 and restraining (r = 
2.5 Å, k = 105 kJ mol
-1
Å
-2
) the distance between the distal His58 hydrogen (HNε) and 
Od.
107,111,114
 Using this structure, flexible docking studies described below were carried 
out to generate OxyHb-HUA complexes. Subsequently, OxyHb-HUA structures were 
manually processed to generate MetHb-HUA starting structures for flexible docking 
studies, in which the bound oxygen molecule was removed, the Fe charge was converted 
from +2 to +3, and the N of His58 was deprotonated. A TNCG minimization was 
performed on MetHb-HUA using the same parameters applied to the OxyHb complex, 
however, the distance restraint between HNε – Od was replaced by HN´ – OGly25 (i.e. closest 
possible hydrogen bond). Schrödinger's LigPrep 2.3 was used to process the HUA 
substrates and generate energy minimized molecular structures prior to docking. 
2.3.2 Customized Induced Fit Docking  
IFD is an accurate flexible receptor – flexible ligand docking protocol 
which predicts binding modes by iterative combination of rigid docking (Glide)
5
 with 
protein structure prediction (Prime).
48,115
  A customized IFD protocol was used to induce 
protein flexibility into the apo structure of OxyHb with the same protocol used for 
MetHb-HUA complexes. The following steps were undertaken with an in-house python 
script developed to automate the process (Figure 2-4): 
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1) Mutated flexible active site residues: The first step of this process involves mutating 
all residues within 7 Å of the oxygen of oxy-heme to alanine. The distal and proximal 
histidines, His58 and His87, respectively, were excluded from this process, as they were 
deemed essential to the structure.  
2) Initial Glide docking: Hydroxyurea analogs were docked into the OxyHb and MetHb 
active sites, using Glide standard precision (Glide SP). Dockings were carried out with 
vdW scaling of 0.5 for the ligand and 0.7 for both receptors, while HO was required to be 
within 2.3 Å
 
of the bound oxygen (Ob) in OxyHb
88
 and 2.5 Å from the deprotonated N 
(His58) in MetHb. We requested 100 poses of partially optimized receptor-substrate 
complexes to allow for extensive conformational examination. 
3) Prime Refinement: Each Glide SP receptor-substrate output pose was refined by 
prime,  which performs side chain prediction by back mutating the alanine residues to 
their initial amino acid. Back mutation was followed by minimization of the entire 
receptor-substrate complex. This was done while retaining the original frozen atoms and 
restraints (k = 200 kJ mol
-1
Å
-2
) from Glide SP. Again, in MetHb the HNε – Od distance 
restraint was replaced by HN´ – OGly25 with the force constant for this interaction reduced 
to 25 kJ mol
-1
Å
-2
. A TNCG minimization with full vdW radii for the receptor-substrate 
complex was again performed using the OPLS 2005 all-atom force field with surface 
generalized Born solvation energies. Following all minimizations, structures within a 40 
kcal mol
-1
 energy window were retained for redocking (~50 – 100 structures).  
4) IFD-XP redocking: Glide extra precision (Glide XP) redocking was performed with a 
single positional restraint for both OxyHb and MetHb. The restraints required HO atoms 
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to be within 2.5 Å of the oxygen Ob for OxyHb and His58 N for MetHb. XP descriptor 
information for the best redocked (i.e. scored) ligand/substrates poses was analyzed.  
                                     
Figure 2-4: The flowchart of IFD protocol followed to predict the binding modes of 
hydroxyurea analogs in OxyHb and MetHb. 
2.4 Results 
Docking results of hydroxyurea analogs into OxyHb
87,88,101,107
 were obtained to 
gain insight into the binding modes and redox reactions that produce NO in SCD 
treatment. The binding modes were analyzed using the Glide XP scoring function, which 
is broken down into individual interaction energies. These descriptors are viewable with 
the “XP Visualizer” program in Maestro.  The score includes favorable energy terms such 
as the chemscore-lipophilic pair term (Lipophilic EvdW), hydrophobic enclosure 
(PhobEn), hydrophobically packed hydrogen bonding (PhobEn HB), chemscore 
hydrogen-bond interactions (HBond), electrostatic interaction (Electro), and low 
XP descriptors 
Glide XP redocking  
Back mutation and Prime minimization with 
pair wise restraints 
Initial Glide SP Docking 
Mutate flexible active site residues within 7 Å  
of Oxy143 
Protein Preparation (Impact Minimization) 
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molecular weight (Low MW). The cumulative penalty term (Penalty) includes intra-
ligand contacts, polar atom burial, amide torsion, and desolvation. The best-docked pose 
for all hydroxyurea substrates in OxyHb was retained for the XP descriptor analysis 
(Table 2-1). From the IFD results, Leu29, Phe33, Phe43, Phe46, Leu48, Val62 and Ala63 
positions underwent substantial change where the RMSD was 0.5-4.36 Å when compared 
to initial positions (Table 2-1A). All RMSD values were calculated with CHARMM
116,117
 
as it was necessary to account for atom reordering that occurred during Prime’s back 
mutation procedure.   
The corresponding substrate representative binding modes are shown in Figure 2-
5.  All substrates except 7 (Figure 2-5b) show HO hydrogen bonded to the bound oxygen 
atom (Ob), and their HN´ hydrogen bonded to the OGly25. 1 and 4 have similar binding 
modes. Only 7 has a unique binding mode, whereas 5, 6 and 8 have congruent binding 
modes. 
 
Table 2-1: XP descriptor analysis derived from IFD-XP redocking of hydroxyurea 
analogs into OxyHb, compared with the reported experimental rate constants.  
Name XP 
score 
Lipophil
-ic 
EvdW 
Phob
En 
HBond Electro Low 
MW 
Pen
ality 
Rate constant k1(min
-1
) 
with OxyHb
 
1 -4.59 -0.45 0.00 -2.77 -0.92 -0.50 0.05 7.54×10
-4
 ± 2.16×10
-5
 
4 -4.42 -0.93 0.00 -2.50 -0.49 -0.50 0.01 3.93×10
-2
 ± 1.68×10
-3
 
5 -6.48 -3.10 -0.68 -2.08 -0.43 -0.50 0.31 6.24×10
-2
 ± 6.18×10
-3
 
6 -5.36 -2.33 -0.25 -1.89 -0.40 -0.50 0.01 8.56×10
-3
 ± 1.87×10
-4
 
7 -4.57 -2.27 0.00 -1.72 -0.09 -0.50 0.01 2.26×10
-3
 ± 8.16×10
-5
 
8 -7.35 -3.54 0.00 -3.13 -0.46 -0.50 0.27 1.94×10
-3
 ± 5.50×10
-4
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Table 2-1A:  Summary  of IFD  studies of  hydroxyurea  analogs  leading  to  
conformational movement  of residues  (RMSD  values,  Å)  within  9 Å around  O2  in  
the  active  site  of  OxyHb  compared  to  its  apo structure 
Residues HU1 HU4 HU5 HU6 HU7 HU8 
G25 0.35 0.26 0.93 1.62 0.83 0.37 
A26 0.31 0.20 0.98 1.60 0.68 1.24 
A28 0.55 0.58 0.83 1.48 0.75 0.77 
L29 1.74 1.94 3.44 2.35 1.70 3.53 
M32 1.23 0.66 0.67 1.33 0.46 0.50 
F33 1.52 4.28 4.36 1.24 0.99 1.52 
T39 1.67 1.51 0.79 0.54 0.48 0.45 
F43 0.37 1.30 0.91 0.54 0.54 0.24 
F46 0.51 0.36 0.75 0.32 0.56 0.52 
L48 2.53 0.49 0.71 2.00 2.63 2.16 
V55 0.69 0.28 1.56 1.35 0.72 1.41 
H58 0.47 1.24 0.98 0.93 0.62 0.59 
G59 0.78 0.29 0.65 1.23 0.91 0.72 
K61 0.91 0.63 0.72 0.61 1.01 0.78 
V62 1.94 1.10 0.82 1.88 1.72 2.12 
A63 0.87 0.33 1.11 1.50 1.39 1.84 
A65 0.29 0.29 0.43 0.57 0.63 0.56 
L66 0.74 0.48 0.68 1.48 2.44 0.76 
H87 0.25 0.25 0.25 0.25 0.25 0.25 
L101 0.28 0.42 0.50 0.81 1.36 0.16 
L105 0.55 0.46 0.43 0.92 1.45 0.32 
 
IFD was also performed for MetHb with the restraints described in the methods 
section. The XP descriptor analysis results are presented in Table 2-2 and Figure 2-6 
illustrates predicted binding poses of 1, 7, and 8. IFD caused the following residues; 
Leu29, Phe33, Phe43, Phe46, Leu48, Val62 and Leu105, to undergo substantial change: 
RMSD 0.6-3.92 Å compared to their respective OxyHb complexes (Table 2-2A). Our 
results show that 7 has the smallest hydrogen bonding contribution in MetHb due to the 
lack of a hydrogen bond between HN´ and OGly25. Also, 5 and 8 have similar binding 
modes with significant hydrophobic stabilization.  
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Figure 2-5: Predicted binding modes of the hydroxyurea analogs, 1 and 7 in OxyHb. 
Carbons of heme and ligands are colored green, oxygen red, nitrogen blue, sulfur yellow, 
hydrogen grey and iron light blue. Hydrogen bonding interactions are shown as black 
dashed lines and the active site loop is highlighted as a yellow ribbon. 
Table 2-2: XP descriptor analysis of all hydroxyurea analogs obtained from IFD-XP 
redocking in MetHb. 
Name XP 
score 
Lipophilic 
EvdW 
Phob
En 
PhobEn 
HB 
HBond Electro Low 
MW 
Penality 
1 -3.27 -0.56 0.00 0.00 -1.76 -0.56 -0.50 0.10 
4 -3.31 -0.95 0.00 0.00 -1.62 -0.30 -0.50 0.07 
5 -7.80 -2.76 -0.78 -1.50 -1.62 -0.78 -0.50 0.16 
6 -3.93 -2.16 0.00 0.00 -1.61 -0.38 -0.50 0.72 
7 -4.13 -2.14 0.00 0.00 -1.33 -0.33 -0.50 0.17 
8 -6.03 -3.42 0.00 -1.50 -1.35 -0.24 -0.50 0.99 
 
 
Figure 2-6: IFD structures for predicted binding modes of the hydroxyurea analogs, 1, 7 
and 8 in MetHb are depicted in 6a, 6b and 6c, respectively.  
 
H58 
G25 
L110 
a) 
H58 
G25 
L110 
b) G25 
L105 
L129 
L110 
H58 
V62 
A28 c) 
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2.5 Discussion  
The current work seeks molecular level insight into the binding modes and 
reactions for a series of hydroxyurea analogs in OxyHb and MetHb. Until now, details of 
these processes have remained elusive, largely due to the lack of co-crystallized structural 
information. Current results combined with previous structural
91,97,101
 and biochemical 
information
87,88,101
 allow for the first prediction of HU (and analogs) binding and 
subsequent reaction mechanism. 
Table 2-2A:  Summary of IFD  studies of  hydroxyurea  analogs  leading  to  
conformational movement  of residues (RMSD values, Å) in MetHb compared to their 
respective OxyHb structures. For comparison we listed conformational movements of the 
same residues shown in OxyHb. 
Residues HU1 HU4 HU5 HU6 HU7 HU
8 G25 0.18 0.43 1.21 0.52 0.18 0.48 
A26 0.17 0.39 1.13 0.49 0.10 1.27 
A28 0.16 0.35 1.10 0.51 0.08 0.35 
L29 0.34 1.27 2.90 1.43 1.18 2.88 
M32 0.36 1.11 1.49 0.59 1.11 1.13 
F33 0.74 0.13 1.02 3.18 0.36 3.96 
T39 0.15 0.34 0.31 0.66 0.13 0.55 
F43 3.21 2.92 3.92 2.70 2.82 2.17 
F46 1.41 2.04 2.63 3.57 1.46 1.31 
L48 0.83 0.76 2.00 1.92 0.62 2.33 
V55 0.20 0.16 1.53 1.63 0.32 1.56 
H58 0.13 0.15 0.28 0.06 0.00 0.14 
G59 0.54 0.32 0.21 0.31 0.08 0.45 
K61 1.16 0.23 0.71 1.54 0.00 0.36 
V62 1.51 1.19 0.20 2.58 1.31 1.43 
A63 0.36 0.08 0.28 0.67 0.08 0.49 
A65 0.43 0.09 0.10 1.14 0.08 0.53 
L66 0.65 0.11 0.17 0.72 0.12 2.07 
H87 0.11 0.39 0.19 0.36 0.20 0.33 
L101 0.15 0.55 0.58 0.41 1.41 0.85 
L105 1.66 1.59 1.79 1.64 1.19 1.90 
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Figure 2-7:  Proposed mechanism of action between hydroxyurea analogs and adult 
hemoglobin a) Reaction scheme 1 demonstrates interaction of 1 with OxyHb to give 
hydroxyurea nitroxide radical (2). b) Reaction scheme 2 shows the possible mechanistic 
interactions between 1/2 and MetHb to produce DeoxyHb and 2.  
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The putative narrow OxyHb substrate binding site consists of several hydrophobic 
residues, oxy-heme, and His58; an imidazole functional group that acts as a ligand gate 
for entry into the OxyHb active-site.
112
 His58 also acts as a proton donor in the proposed 
mechanism (Figure 2-7a). In this reaction, the nature of Fe-O2
 
bonding exists in 
accordance with the Weiss bonding model,
95,107,114
 in which a single electron transfer 
from Heme-Fe
II
 to Ob leads to Heme-Fe
III
-O2
-
 complex.
95,118
 
Soon after the radical localizes on the bound oxygen, we hypothesize it will be 
transferred to the hydroxyurea substrates by abstracting HO, leaving 2 (Figure 2-7a). 
Subsequently, negative charge generated on Od will abstract hydrogen from His58 
forming H2O2. Since the first step involves HO abstraction in all the hydroxyurea 
substrates, we performed IFD studies with an explicit positional restraint enforcing the 
HO to be within 2.5 Å of the Ob. The OxyHb studies revealed that all analogs fit well in 
the active site that is surrounded by various hydrophobic residues. Leu29, Phe33 and 
Val62 experienced the greatest active site conformational rearrangement due to 
accommodation of substrates during the IFD procedure (Table 2-1A).   
Figure 2-5 illustrates that all hydroxyurea analogs preferentially form a hydrogen 
bond to OGly25 except for 7, due to the absence of HN´. Hence, the total XP hydrogen 
bonding score for 7 (Phob En HB + Hbond) derived from IFD has the smallest 
contribution to the total Glide score. The hydrophobic substrate groups, phenyl, n-butyl, 
and methoxyphenyl bonded to N of 5, 6 and 8, respectively, occupy a well-defined 
hydrophobic cavity in OxyHb created by Leu29, Met32, Phe43, Phe46, Leu48, Val55 and 
His58. These additional hydrophobic interactions (Lipophilic EvdW + PhobEn) increased 
stabilization by 2.5-3.8 kcal/mol. The enhanced hydrophobic contribution of 5 and 8 
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F33 
5 
Od 
Ob 
L29 
H58 
compared to 6 can be attributed to partial π-stacking between the side chain of His58 and 
their corresponding phenyl and methoxyphenyl substituents; clearly seen in Figure 2-8. 
Substrate 8 has even better binding affinity to OxyHb than 5 due to the additional 
hydrophobic contribution from the methoxy group with Leu29, Phe33, Phe46 and Val55 
(Figure 2-5). The tighter binding may be correlated to 8 having a smaller rate constant 
than 5 when reacting with OxyHb (Table 2-1).
88
  
 
 
 
 
 
Figure 2-8: Comparison of the induced fit conformation of OxyHb with 5 (in dark green) 
and apo structure of OxyHb (in yellow). All hydroxyurea analogs in general induce 
receptor flexibility by generating a Leu29 flip, which further moves away Phe33.  
Custom IFD was undertaken based on the proposed mechanism in Figure 2-7b. 
Results showed that 7 has less hydrogen bonding stabilization in MetHb compared to 
OxyHb. This stabilization is hypothesized to be necessary to retain the substrate 
radicals/anion in MetHb (Figure 2-7b) and suggest an explanation as to why 7 does not 
form a low-spin MetHb-HUA complex,
88
 a pre-requisite in the formation of HbNO. A 
closer inspection of docking scores and XP descriptors reveals only modest differences in 
stabilizations and penalties comparing 7-OxyHb and 7-MetHb. This suggests that steric 
clashes, which have been previously hypothesized as the cause of 7 not producing NO are 
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not likely responsible. Again, this supports our hypothesis that the lack of hydrogen 
bonding to OGly25 is the more likely explanation.  
 To further support our hypothesis, that steric repulsion is not the cause of 7’s lack 
of reaction, we have modified analog 6 when bound to MetHb by replacing the hydrogen 
bound to N with a methyl group constructing 6a. This complex “should” represent a 
more sterically hindered environment. The protein complex, 6a, was minimized until the 
RMSD reached a maximum cutoff of 0.30 Å from the explicit coordinate geometry of 6 
using the TNCG algorithm and later the ligand was scored in place by the Glide XP 
docking algorithm. XP descriptors were obtained to compare 6 and 6a (Table 2-3). As 
anticipated, the Δhydrogen bond difference was 0.92 kcal/mol, indicating a significant 
loss of hydrogen bonding stability for 6a. The methyl bonded to the N atom improved 
the lipophilic vdW contribution by 0.1 kcal/mol and surprisingly reduced the penalties 
from 0.72 to 0.16 kcal/mol. These results again demonstrate the importance of the HN´ 
atom for hydrogen bonding and shows that adequate space is available to accommodate 
additional substituents on the N atom.  
Table 2-3: XP descriptor analysis of 6, 6a and 7 obtained from IFD-XP docking in 
MetHb. 
Name Docking Hbond Lipophilic HBond Electro Low Penalties 
 score CO EvdW   MW  
  Res      
6 -3.93 Gly 25 -2.16 -1.61 -0.38 -0.50 0.72 
6a -3.62 None -2.25 -0.77 -0.26 -0.50 0.16 
7 -4.13 None -2.14 -1.33 -0.33 -0.50 0.17 
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The XP descriptor analysis explains the observed difference in the binding modes 
of 5 and 8 in OxyHb and MetHb (Figures 2-5 and 2-6, respectively). The different 
conformation of 5 and 8 in MetHb is attributed to the loss of a hydrogen bond interaction 
with Ob that is required to stabilize the protein-substrate complex. Therefore hydrophobic 
substrate groups, phenyl and methoxy phenyl on the N  atom of 5 and 8, respectively, 
occupy a different well-defined hydrophobic cavity created by Gly25, Ala28, Val62, 
Leu101, Ser102, Leu105 and Leu129 in MetHb (Figure 2-6c). We also observe contrary 
binding affinities in the case of MetHb, as shown by 5 having a lower docking score than 
8 (Table 2-2). We attribute this to unfavorable steric interactions by the methoxy 
subgroup within the hydrophobic cavity that lead to high penalties. Hence, we propose 
hydroxyurea substrate design for effective NO release should involve optimizing the 
interactions between hydrophobic substituent (X) and hydrophobic residues in the active 
site of OxyHb and MetHb while ensuring that there is a hydrogen bond between the HN´ 
atom and OGly25.  
To gain further insight into the importance of Gly25 and the aforementioned 
hydrophobic residues, we examined active site conservation using a protein binding site 
detection tool (ProBiS)
103-105
 along with ClustalW.
106
 ProBiS uses a database of 29,412 
non-redundant PDBs to represent structural diversity. This group is searched using a 
novel algorithm based on the clique approach
119
 that effectively identifies binding site 
topologies with similar geometric and physicochemical properties to the query protein. 
Using the adult hemoglobin HbA [PDB ID : 2DN1 – A chain] as the query protein 
ProBiS yielded 302 protein structures with similar binding site topologies. The proteins 
with Z-scores (statistical measure of protein similarity) > 2 were analyzed with additional 
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similarity calculated using local structural alignment. The local structural similarity Z-
scores along with the Pfam entities are depicted in Appendix (Figure A-2).  
ProBiS’s structure based sequence alignment results showed the most conserved 
active site residues to be: Phe43, His58, Val62, Leu83, His87, Phe98, Leu100, Leu101, 
and most conserved substituted residues to be: Gly25, Leu29, and Phe46. Conservation is 
present across all 302 non-redundant structures with human globin proteins like 
Cytoglobin, Myoglobin, β-HbA, δ-HbA, and Neuroglobin having similar binding sites to 
α-HbA and high sequence identity. Sequence alignment using these six proteins was 
subsequently carried out with ClustalW. Results revealed Gly25, Phe43, His58, Val62, 
and His87 to be the most conserved residues with Phe46, Leu83, Phe98, Leu100, and 
Leu101 being the most conserved substituted residues (Figure 2-9 and Figure A-3). The 
identification of conserved Gly25 and important hydrophobic residues provides further 
evidence supporting our above recommendations.  
CLUSTAL 2.1 multiple sequence alignment 
 
2DN1_A|SEQUENCE      ---------------VLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTK 40 
2DN1_B|SEQUENCE      --------------VHLTPEEKSAVTALWGKV--NVDEVGGEALGRLLVVYPWTQ 39 
1SHR_B|SEQUENCE      --------------VHLTPEEKTAVNALWGKV--NVDAVGGEALGRLLVVYPWTQ 39 
2DC3_B|SEQUENCE      KVPGEMEIERRERSEELSEAERKAVQAMWARLYANCEDVGVAILVRFFVNFPSAK 60 
3RGK_A|SEQUENCE      ---------------GLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETL 40 
1OJ6_D|SEQUENCE      ----------------MERPEPELIRQSWRAVSRSPLEHGTVLFARLFALEPDLL 39 
                                     :   :   :   *  :       *   : *::   *    
Figure 2-9:  Mutiple sequence alignment studies of human globin chains includes α-Hb, 
δ-Hb, β-Hb, Cytoglobin, Myoglobin and Human Neuroglobin using Clustal W2 in which 
2DN1-A is used as the query protein. And the various legends given below the sequences 
represent  "*" residues are identical, ":" observed conserved substitutions, "." observed 
semi-conserved substitutions. The amino acid residues are colored according to their 
physio- chemical properties in which red implies small hydrophobic (AFILMPVWY); 
blue implies acidic (DE); purple implies basic (HKR) and green implies with hydroxyls 
and amines and basic too (CGHNQSTY) 
As previously mentioned, King and co-workers observed a large rate increase for 
5 and 8 as compared to 1. They attributed this effect to the presence of aromatic 
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substituents and their ability to stabilize the initially formed nitroxide radical (similar to 
2).
88
 There is some controversy surrounding this prediction as Rohrman and Mazziotti 
computationally examined the radical stabilization of King’s HU derivatives.89 They 
predicted the enhanced rate of 5 was most likely due to transition state stabilization as it 
had a very small radical stabilization, in apparent contrast with King’s hypothesis. 
Rohrman et al. also suggested that longer alkyl chains at the X position should improve 
substrates, however, they were unable to confirm these were sterically allowed in the 
OxyHb active site. From the large RMSD’s (0.5-4.36 Å) induced by substrate docking in 
OxyHb, we conclude the hydrophobic pocket is a possible source of the previously 
hypothesized transition state stabilization. Additionally, the newly predicted HO – OGly 
hydrogen bond helps to further clarify the observed reactivity and positions itself as 
another possible source of transition state stabilization.  
Although the exact mechanism of radical production from hydroxyurea analogs 
with MetHb is unclear, our docking studies give insight into likely reactions.  Examining 
the importance of HN´ binding contributions to the total binding affinity lead us to explore 
the low-spin MetHb-HUA complex formation. This yields three possible hypotheses A, 
B, and C for MetHb reaction scheme 2. Hypothesis A entails a new substrate molecule 
entering MetHb by replacing the existing substrate radical from reaction 7a as proposed 
by King and co-workers.
88
 However, it is unclear as to what happens to the radical once it 
leaves the active site as it will most likely get quenched and not be retained for the third 
reaction (Figure 2-3). In hypothesis B, the substrate radical will be retained in the active 
site through the stable hydrogen bonding interaction between HN´ and OGly25. 
Furthermore, adequate data in the literature
120-122
 supports the plausibility of hypothesis 
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B, in which various electron transfer reactions occur commonly either in solvent media or 
intra- or inter-tetramer subunits of hemoglobin. The complex array of hemoglobin 
electron transfer mechanisms indicates that an electron can easily be transferred to the 
hydroxyurea nitroxide radical to form the hydroxyurea nitroxide anion.  The anion would 
then coordinate to the ferric iron of MetHb to form a low-spin MetHb-HUA complex. 
Hypothesis C is similar in mechanistic detail to hypothesis A, except that the 
hydroxyurea analog substrate is reformed from the interaction of the substrate radical and 
a hydrogen radical abstracted from an active site water molecule. Because the active site 
is at the surface of hemoglobin subunits, water should be available to facilitate this 
mechanism. After scrutinizing hypotheses A, B, and C, it seems likely that either the 
hydroxyurea anion substrate or the hydroxyurea substrate radical will be retained in the 
active site by the hydrogen bond to OGly25 and react to form the low spin MetHb-HUA 
complex. 
2.6 Conclusion 
Sickle cell anemia is an inherited disease that causes sickling of red blood cells. 
There is a growing need for drugs that can effectively release NO to ease the intense pain 
and also elevate HbF levels that possess better oxygen affinity than HbA. Unfortunately, 
the discovery of novel drug substrates that produce effective NO release has been 
hindered by the lack of structural information focusing on the interaction between Hb and 
hydroxyurea, the only FDA approved SCD treatment. In the current work, we employed 
an effective docking protocol to obtain the first bioactive 3D models of OxyHb and 
MetHb with a congeneric series of hydroxyurea analogs. Furthermore, we proposed 
reaction mechanisms (Figure 2-7a and 2-7b) based on combined information obtained via 
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binding modes and previous biochemical data. IFD results and the proposed mechanisms 
offer new insights into key intermolecular interactions that may be exploited during 
rational substrate/drug design.  
The current work elucidates the importance of the HN´ atom and its contribution as 
a vital stabilizing interaction. This sheds new light onto the previously observed HUA 
HN´ requirement.
88
 XP descriptor analysis also yields insight into key structural 
requirements for small molecules interacting with OxyHb and MetHb. Substrates having 
aromatic functional groups are shown to have better binding affinity than other 
hydroxyurea analogs in Hb due to their favorable van der Waals, π-stacking, and 
hydrophobically packed hydrogen bonding energy
5
 contributions. Our observations show 
that to achieve better substrate design for effective NO release, it is important to consider 
the exploitation of this key HN´ bonding interaction with OGly25, along with maximizing 
the hydrophobic interactions within the deep hydrophobic pocket of hemoglobin. 
Furthermore, from observed binding site similarities and high % sequence identities to α-
HbA, we hypothesize that hydroxyurea analogs may undergo similar biochemical 
interactions across the human globin family of proteins. In fact, other heme-based 
enzymes, for example Catalase,
123,124
 have already been identified as hydroxyurea targets. 
In the future, we plan to explore the binding modes and reaction kinetics of these 
additional redox active enzymes.  
 
 
 
 42 
 
2.7 Acknowledgments 
 I would like to thank Professor Wayne Guida, Professor Randy Larsen, Dr. Vasiliki 
Lykourinou and Dr. Kai Lang for their helpful discussions. I would like to acknowledge 
my assistance received through H.L.W’s funding from NIH (1K22HL088341-01A1) and 
the University of South Florida (start-up). Computations were performed on local USF 
computers and the USF Research Computing Center, where NSF-funded computational 
resources (under Grant No. CHE- 0722887) were greatly appreciated.  
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
 
 
Chapter 3: How Does Catalase Release Nitric Oxide? A 
Computational Structure Activity Relationship Study 
 3.1 Abstract  
Hydroxyurea is the only FDA approved medication for treating sickle cell 
anemia in adults. The primary mechanism of action induces pharmacological 
elevation of nitric oxide (NO) levels and leads to propagation of fetal hemoglobin. 
Despite this overall understanding, specific details about the hydroxyurea (HU) 
interaction with various heme based enzymes to produce NO remains unknown. 
Recent experimental studies indicate the interaction of HU with human catalase 
compound I produces NO. Presently, we combine ﬂexible receptor-ﬂexible substrate 
induced fit docking (IFD) with energy decomposition analyses to examine the atomic 
level details of a key step in the clinical conversion of HU to NO. Substrate binding 
modes of seven HU analogs with catalase compound I were investigated to determine 
the essential properties necessary for effective NO release. Two major binding poses 
provides insight into possible reaction mechanisms which would result in NO 
production. Further results show that, anion/radical intermediates produced as part of 
these mechanisms would be stabilized by hydrogen bonding interactions from distal 
residues His75, Asn148, Gln168, and oxoferryl-heme. These details will contribute to 
the design of superior NO releasing agents, hence furthering drug design efforts 
targeting sickle cell disease.  
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3.2 Introduction 
 
Sickle cell disease (SCD), an inherited monogenic disorder, results from the 
mutation of the 6
th
 amino acid in the -globin gene changing from the polar amino acid glutamic 
acid to the non-polar residue valine.
74
 This mutation forms defective, sickled, hemoglobin 
(HbS). Upon deoxygenation, HbS undergoes polymerization into long fibrils that 
ultimately results in "sickled" red blood cells. Symptoms of SCD are intense pain, 
microvascular vaso-occlusion, acute chest syndrome, strokes, severe multi-organ damage, 
and even death.
75,125,126
 In 1998, the FDA approved hydroxyurea (HU) as a SCD 
treatment
127
 and it remains the only remedy for severe cases.
128
 HU elevates nitric oxide 
(NO) levels subsequently inducing fetal hemoglobin (HbF) production, which mitigates 
sickle cell severity. HU augments HbF synthesis by raising -globin gene expression through 
the activation of  NO dependent soluble guanylyl cyclase (sGC) pathway
85
 in the human erythroid 
progenitor cells. Further, NO generated from HU assists in maintaining normal blood 
pressure, smoothening muscles, producing relaxation, and improving blood ﬂow to assist 
patients with intense pain resulting from inﬂammation. Increased NO bioavailability also 
improves red cell rheological properties and endothelial cell interactions. Moreover, HU 
ameliorates antioxidant defense by decreasing lipid peroxidation levels by at least 30 due 
to its contribution to higher catalase activity in SCD patients.
129
 SCD patients undergoing 
HU therapy are known to produce various intermediates like C-nitroso formamide, 
nitroxyl, nitric oxide, nitrates, and nitrites, which have numerous human physiological 
effects.
130  
A recent study by King and co-workers
123
 showed that HU interacts with oxy and 
deoxyHb resulting in slow NO production rates. This did not correlate with the 
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observed increase in NO concentrations in patients undergoing HU therapy. The 
discrepancy can be attributed to the interaction of HU competing with other heme 
based enzymes
88,101,123,124,131
 such as catalase, human globins, and peroxidases that are also 
known to produce NO. Elucidation of the molecular level interactions between HU and 
each of these heme-based enzymes is critical to understanding NO metabolite 
concentrations in patients undergoing HU therapy. Specifically, hydroxyurea analogs 
(HUA, Figure 3-1) previously established to be a good diversity set through interaction 
with hemoglobin,88 will be used for a computational structure activity relationship 
(SAR) study with catalase. 
 
Figure 3-1: Hydroxyurea analogs tested for their structure activity relationship by King 
and co-workers in hemoglobin. The specific nomenclature used for diferent hydrogen and 
nitrogen atoms is: nonhydroxyl nitrogen atom (N ), nitrogen attached to hydroxyl moiety 
(NO), hydrogen atom bonded to N' atom (HN′), hydrogen bonded to NO atom (HN), 
hydroxyl hydrogen as (HO), and substituent alkyl/phenyl groups bonded to the 
nonhydroxyl nitrogen atom (X). We used hydroxyurea as a generic model to define the 
various groups. 
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Catalase enzymes are typically classified into three sub-types: mono-functional, 
bifunctional catalase peroxidases, and pseudo catalases.
132
 Mono-functional catalases, 
known as mammal catalases, are commonly present in animals. Their quaternary 
structures are similar across organisms and are generally present as a tetramer with four 
equal subunits consisting of a hydrophobic pocket that strongly binds heme prosthetic 
groups. The catalase heme group exists as a pentavalent coordinated system with ferric 
iron having four coordinate bonds to porphyrin nitrogens while the fifth bond is to the 
proximal tyrosine. Compared to most other enzymes, catalases are more resistant to pH 
change and thermal denaturation due to their stable tetrameric interactions.
133
 They are 
also known to play an important role in soothing inﬂammation, mutagenesis, and 
prevention of apoptosis.
132
 Catalases also promote higher antioxidant defense mechanisms 
against reactive oxygen species (ROS);
129,134
 reducing oxidative stress, inﬂammatory 
response, and membrane lipid peroxidation levels in SCD patients undergoing HU therapy. 
 
Catalase is primarily known for combating ROS such as hydrogen peroxide (H2O2). 
Ferric catalase protects hemoglobin by dissociating two H2O2 molecules sequentially in 
normal human erythrocytes into water and oxygen molecules.
132
 The reaction cycle
135
 
begins with high spin ferric (Fe
III
) heme interacting with H2O2 to form an oxoferryl 
porphyrin cation radical  (O=Fe
IV
-Por
+•
),  also known as compound I (CpdI). The 
second H2O2 molecule reduces CpdI to its native resting state enzyme. 
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Figure 3-2: Proposed reaction mechanism by Fita and Rossmann,
136
 for H2O2 interaction 
with catalase CpdI. Reaction scheme involving His mediated mechanism of action and 
reaction scheme describing direct mechanism of action. 
 
Two possible mechanisms have been proposed for the H2O2-catalase CpdI reduction: 
a His mediated mechanism and a direct mechanism. The His mediated mechanism, 
proposed by Fita and Rossmann,
136
 is comprised of sequential hydrogen transfer to CpdI 
with the distal His playing a catalytic role. This differs from the direct mechanism
137
 
where the hydrogen atoms are successively transferred from H2O2 to the oxoferryl group 
in the active site with His only playing an intermolecular role (Figure 3-2). The direct 
mechanism is proposed by Kato and co-workers. 
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Figure 3-3: Generic representation of catalase mediated NO production from 
hydroxyurea by King and co-workers. The reaction step highlighted in red box shows the 
intermediacy of C-nitroso formamide, a prerequisite precursor for NO formation. 
 
King and co-workers have undertaken extensive EPR spectroscopic studies to explore 
a similar reaction profile comprising of catalase in a series of reactions with HU to 
produce NO.
123,124,130
 The catalase mediated NO reaction begins with the production of 
CpdI, similar in mechanism to H2O2. CpdI interacts with HU to produce C-nitroso 
formamide followed by the formation of nitroxyl (HNO) upon hydrolysis. Subsequently 
HNO interacts with native ferric catalase to generate a ferrous NO-catalase complex 
(Figure 3-3), which serves as a source of NO. The released NO was judged by 
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Oxyhemoglobin assay and EPR spectroscopic trapping studies.
123
 However, the detailed 
mechanism of action remains unclear due to the lack of a 3D bioactive crystal structure, 
necessary to probe the atomistic interactions between human catalase and HU. Herein we 
seek a greater understanding of the atomistic interactions between catalase CpdI and the 
hydroxyurea analog diversity set by a combination of ﬂexible receptor-ﬂexible substrate 
induced fit docking (IFD), bioinformatics, and quantum mechanics (QM) studies. 
3.3 Computational Details  
X-ray crystal structure coordinates of catalase were obtained from the protein data 
bank [PDB: 1DGG].
138
1DGG is a high resolution, 1.5 Å tetramer containing NADPHs 
and heme prosthetic groups and bound cyanide. The prosthetic heme iron exists in the 
hexa coordinate state. The NADPH region is hydrated, whereas the immediate active site 
and -barrel regions are devoid of structural waters. Chain A of PDB: 1DGG was used and 
the cyanide group was manually back mutated to an oxygen atom along with 
incrementing the charge on iron to +4 to replicate CpdI. The IMPACT molecular 
mechanics program
139
 was used to correct bond orders, add missing hydrogens, and 
remove co-crystallized water molecules not present in the active site. The histidine 
protonation state HSD (protonated on N1 only) was selected for His75 corresponding to 
the His mediated Fita-Rossmann mechanism.
136
 A Truncated Newton Conjugate 
Gradient (TNCG) minimization was performed using the OPLS-2005 force field. The 
oxoferryl-heme was frozen in a constant dielectric of 2. All substrate structure atomic 
coordinates were built and minimized using Schrodingers LigPrep 2.3
140
 module before 
preliminary docking investigations. 
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Enzyme ﬂexibility is a key component in determining receptor/substrate 
recognitions. We used ﬂexible receptor-ﬂexible ligand docking, also known as 
IFD
45,46
 to characterize conformational changes in catalase CpdI upon HUA binding. 
The IFD protocol uses a combination of rigid docking (GlideXP) with protein 
structure prediction (Prime).
46
This methodology has been well validated and 
successfully applied to various biological problems including loop predictions,115,141 
homology modeling,70 fragment based docking,
69
  and enrichment studies.
68,142
 The 
various steps implemented in sequential order during the IFD protocol are described 
below:  
1) Active site residues mutated to Ala: Temporary mutation of all side chains residues 
within 9 Å of the oxoferryl oxygen to Ala that impede ligand access into active site. 
The distal His75 was excluded from this process as it is essential to the structure's 
integrity.  
2) GlideSP docking: Rigid GlideSP docking of HUAs was performed against the 
mutated catalase CpdI structure with softened van der Waals potential to reduce 
sterical clashes and increased Coulomb-vdW non bonded interaction energy cutof 
value to 100 kcal mol-1 to generate more poses. Further, dockings were performed by 
scaling the vdW radii by a factor of 0.5 for the ligand and 0.7 for the receptor to 
generate an initial ensemble of docked poses. 300 poses of partially optimized 
receptor-substrate complexes were requested. 
3) Protein refinement/minimization: The GlideSP docked complexes were refined by 
prime's structure prediction tool using the OPLS-2005 force field and generalized 
Born solvation model.
48,49,143
 The alanine residues were back-mutated to their initial 
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amino acids. In prime refinement mode, IFD uses a three step procedure to sample 
side chain conformations and predict ligand-residue orientations. a) Rotamer libraries 
developed by Xiang and Honig
143
 were used to sample the side chain conformations. 
All side chains within 9Å of the bound oxygen in the oxoferryl group were back 
mutated simultaneously in a random rotamer state. b) Each side chain is then 
minimized sequentially using the single side chain procedure. This protocol involves 
minimization of a single side chain (< 0.001 kcal mol-1     rms gradient) in 
cartesian space by freezing all other residues. The procedure is repeated for all 
residues until convergence is achieved. c) Finally, a TNCG minimization with full 
vdW radii was performed to resolve any remaining sterical clashes. In prime 
minimization mode, the side chain sampling is turned of (step 3a). That is, the 
rotamer library sampling is not performed and sequential side chain minimization is 
carried out (step 3b, 3c). 
4) GlideXP redocking: The substrates within a 40 kcal mol-1 energy window of the 
lowest energy structure from the prime refinement step were redocked into the 
induced fit structures. GlideXP was performed with full vdW scaling for both the 
receptor and substrate. 500 poses were requested for the GlideXP redocking and 
ranked based on the GlideXP score. XP descriptors were generated by fragmenting 
the composite scoring function into various interaction energies to analyze the docked 
poses.  
The interaction energies are described by GlideXP terms. The reward term 
includes: HBond, a generic chemscore hydrogen bonding pair term;
16
 PhobEn Hb, a 
hydrogen bond in protein hydrophobic enclosure; PhobEn, a hydrophobic enclosure 
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term; LipophilicEvdW, a chemscore-lipophilic pair term; Electro, an electrostatic 
contribution; Sitemap, complementary non hydrogen bonding interactions; and 
LowMW, a reward for having lower molecular weight. The penalty term consists of:  
RotPenal, a rotatable penalty for constricting ﬂexible ligands, and XP Penalties, a 
collective combination of intraligand contact, polar atom burial, amide torsion, and 
desolvation. The IFD protocol successfully generated binding modes causing Val74, 
Val116, Phe153, Phe161, Ile165, and Gln168 to undergo substantial side chain 
motion (rmsd's >1Å) in comparison to their apo structures. We used 
CHARMM
117,144,145
 to compute side chain rmsds accounting for the two fold 
symmetry of the phenylalanine side-chains in addition to the atom renumbering that 
took place in the prime back-mutation step. 
 3  .  4   Results and Discussion  
The aforementioned HUAs were initially tested by King and co-workers
88
 for their 
efficacy to produce NO while interacting with adult human hemoglobin. Analogs 1, 5, 6, 
and 8 produce NO due to the presence of the -NHOH group and the HN′ used to stabilize 
the radical intermediates by a hydrogen bond to Gly25.
146
 However, this difers from the 
present case of catalase CpdI wherein these analogs can only form the C-nitroso 
formamide intermediates to produce NO. And currently, we do not have x-ray crystal 
structures to comprehend the key interactions between HUAs and catalase CpdI to form 
the necessary C- nitroso formamide intermediates, hindering HUA substrate design 
process. Here we explore catalase CpdI substrate specificity with the same HU derivatives 
and predict reaction profiles for releasing NO. Further, IFD was coupled with the XP 
descriptor analysis to probe interaction energies. The docking protocol was validated by 
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comparing with a QM/MM optimized structure previously generated by Alfonso- Prieto 
et al.
137
 that contains a intermolecular hydrogen bonding array between H2O2 and catalase 
CpdI (Figure 3-4). The H2O2 pose generated using our IFD protocol matched that of the 
QM/MM optimized structure along with its networked intermolecular hydrogen bonds 
between -NH2 of Asn148 as a hydrogen bond donor interacting with the lone pair of the 
adjacent hydroxyl group from the H2O2. Further, the second hydroxyl group serves as the 
hydrogen bond donor for the N of His75. 
  
Figure 3-4: Inter-molecular hydrogen bonding network observed for the H2O2 docking 
orientation in catalase CpdI active site. Protein carbons are colored in cyan; CpdI 
carbons, yellow-green; oxygens, red; nitrogens, blue; hydrogens, white; and iron, light 
blue. Dotted yellow lines represent the hydrogen bonding interactions and the ribbons 
have red for -helices and cyan for --sheets. 
The IFD protocol produced an ensemble of induced-fit catalase CpdI complexes, 
which were clustered into five groups for each HUA from the diversity set. Two 
predominant pose conformations were obtained for most HUAs and were categorized as 
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pose A and pose B orientations. The top scoring poses from each cluster were used for 
further analysis. Pose A and Pose B exist for HUAs 1, 5, 6, and 8 while 7 has only pose B 
orientations. Neither 3 nor 4 have pose A or pose B due to the absence of -NHOH group. 
Pose A orientations have the -NH2 of Asn148 as a hydrogen bond donor interacting 
with the lone pair of the hydroxyl from the HUA. This hydroxyl group serves as the 
hydrogen bond donor for the N of His75. The extensive hydrogen bond network 
continues by the HN′ of the HUA hydrogen bonding with the oxoferryl group of CpdI 
(Figure 3-5). Pose B orientations consist of a similar hydrogen bonding network with a 
slight variation from pose A. In pose B, the hydrogen bond network is exclusively formed 
by the -NHOH moiety (Figure 3-6). The HN is hydrogen bonded to the oxoferryl group 
instead of the HN′ as in pose A. Both poses have the the -C=O moiety hydrogen bonded to 
-NH2 of Gln168 of the HUA except for 1 in pose B. However, 1 in pose B still consists 
of a hydrogen-bond with Gln168 formed by HN' atom. XP descriptors of the top scoring 
poses in catalase CpdI were retained and analyzed (Table 3-1) along with the binding 
orientations (Table 3-1A). The active site is stabilized by the extensive hydrogen bonding 
network and a hydrophobic pocket created by Val73, Val74, Val116, Phe153, 
Phe161,Pro162, Phe164, and Ile165. These stabilization interactions suggest that the 
radical or anion intermediates of HUAs undergo transition state stabilization. Moreover, 
significant movement of Phe161 and Ile165 is needed to accommodate bulky substituents 
of HUAs ranging from ethyl to methoxyphenyl groups (Table 3-2) as observed by the 
RMSD calculations undertaken using CHARMM program.  
 
 55 
 
 
 
Figure 3-5: Predicted pose A binding orientations of hydroxyurea analogs  1(5a) and 
8(5b) in catalase CpdI. Carbons for CpdI, substrate and protein are colored in yellow-
green, yellow and cyan; oxygens, red; nitrogens, blue; hydrogens, light yellow; and iron, 
magenta. Dotted red lines represent the hydrogen bonding interactions and the ribbons have 
red for -helices and cyan for -sheets. 
 
 
 
Figure 3-6: Predicted binding orientations of hydroxyurea analogs 1(6a), 7(6b) and 8(6c) 
for pose B conformations in catalase CpdI. These analogs predominantly formed pose B 
orientations than pose A like orientations. They all have same hydrogen bonding pattern 
similar to hydrogen peroxide. 
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Table 3-1. XP descriptor analysis showing the contribution of various GlideXP terms in kcal mol
-1
 for all pose A and pose B 
conformations of HUA’s. 
Title GScore HBond Phob 
EnHB 
PhobEn Lipophilic 
EvdW 
RotPenal Penalties Electro Sitemap LowMW 
 
1 - pose A  -5.16  -2.92  0.00  0.00  -0.53  0.00  0.05  -0.86  -0.40  -0.50   
1 - pose B  -4.62  -2.55  0.00  0.00  -0.60  0.00  0.02  -0.58  -0.40  -0.50   
3  -3.95  -1.89  0.00  0.00  -0.38  0.00  0.02  -0.80  -0.40  -0.50   
4  -5.51  -2.93  0.00  0.00  -0.78  0.00  0.00  -0.90  -0.40  -0.50   
5 - pose A  -8.41  -1.94  -1.39  -1.50  -3.04  0.55  0.28  -0.65  -0.22  -0.50   
5 - pose B  -7.43  -2.77  0.00  -0.94  -2.89  0.55  0.13  -0.62  -0.40  -0.50   
6 - pose A  -5.94  -2.55  0.00  -0.85  -2.22  1.37  0.14  -1.01  -0.31  -0.50   
6 - pose B  -5.92  -2.78  0.00  -0.83  -2.16  1.37  0.10  -0.73  -0.40  -0.50   
7 - pose B  -2.64  -2.13  0.00  0.00  -1.93  0.68  2.40  -0.83  -0.33  -0.50   
8 - pose A  -7.39  -2.28  -1.50  0.00  -2.87  0.61  0.38  -0.83  -0.40  -0.50   
8 - pose B  -5.84  -1.87  0.00  0.00  -3.26  0.61  0.02  -0.57  -0.28  -0.50   
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Table 3-1A. Summary of IFD refinement binding orientaions (# corresponds to number) 
 
 
 
 
 
 
 
 
 
3 .   4 .  1 IFD results for all HUA's   
N-hydroxyurea (1): Hydroxyurea, also known as hydroxycarbamide, is used as an 
antisickling, antineoplastic agent.
147,148
 IFD produced an ensemble of 52 binding 
orientations for 1. Clustering produced two dominant clusters with the following number 
of poses in each cluster: Pose A (26) and pose B (13). Pose A (Figure 3-7a) had more 
stabilization compared to pose B (Figure 3-7b) due to hydrogen bonding and electrostatics 
confirmed by the XP descriptors (Table 3-1). After prime refinement, the residues that 
experienced significant movement along with their respective side chain rmsd deviations 
when compared to the apo structure of catalase CpdI for pose A were (Val116 - 1.36Å; 
Ile165 - 1.04Å)  whereas (Val116 - 1.35Å; Gln168 - 1.37Å) moved in pose B (Table 3-2).  
HUA 
NO 
release 
NHOH 
Top 
pose 
# binding poses # Hydrogen bonds 
Total poseA poseB acceptors donors 
1  yes  yes  A  52  26  13  2  3   
2  no  no  NA  NA  NA  NA  2  2   
3  no  no  NA  83  NA  NA  2  2   
4  no  no  NA  80  NA  NA  2  2   
5  yes  yes  A  55  18  9  2  3   
6  yes  yes  A  110  20  58  2  3   
6a  NA  yes  B  32  2  18  2  2   
6b  NA  yes  B  67  13  37  2  2   
7  no  yes  B  22  0  16  2  2   
8  NA  yes  A  60  17  25  3  3   
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Table 3-2. Summary of flexible docking studies of HUA’s that caused the following 
residues to undergo substantial conformational movements around 9 Å  of oxoferryl 
moiety in catalase CpdI in comparision to the starting structure (RMSDs in Å ) 
 
O-methyl N -hydroxyurea (3): This substrate commonly known as 1-methoxyurea 
contains two donors and two acceptors available for hydrogen bonding. Experimental 
results indicate that 3 failed to produce NO when interacting with Hb due to the absence 
of the -NHOH group.
88
 IFD produced 83 orientations, but neither pose A or pose B can 
produce C-nitroso formamide due to the lack of the -NHOH moiety. The major cluster 
consisted of 27 docked conformations with the top scoring pose receiving energy 
 
1 3 4 5 6 7 8 
Residues pose 
A 
pose 
B 
  pose 
A 
pose 
B 
pose 
A 
pose 
B 
 pose 
A 
pose 
B 
Val74  0.20  0.24  0.09  0.07  0.28  1.40  0.32  0.32  0.24  0.60  0.79   
Val 116  1.36  1.35  0.21  1.36  0.12  1.35  0.10  0.42  0.05  0.09  0.13   
Pro129  0.13  0.15  0.14  0.26  0.03  0.14  0.11  0.22  0.09  0.10  0.07   
Gly131  0.02  0.03  0.04  0.04  0.04  0.04  0.04  0.04  0.04  0.04  0.04   
Asn148  0.10  0.07  0.12  0.08  0.10  0.06  0.06  0.07  0.06  0.06  0.08   
Phe153  0.08  0.06  0.65  0.11  0.09  0.09  0.05  2.24  0.08  0.09  0.08   
Phe154  0.06  0.06  0.27  0.09  0.05  0.07  0.04  0.78  0.08  0.05  0.06   
Phe161  0.20  0.08  0.07  0.05  2.73  2.79  2.94  1.37  2.91  3.18  3.17   
Phe164  0.10  0.16  0.55  0.25  0.31  0.19  0.16  0.38  0.38  0.25  0.19   
Ile165  1.04  0.06  0.11  0.12  0.70  0.21  0.93  0.17  0.96  1.16  1.23   
Gln168  0.70  1.37  0.38  0.47  0.44  0.55  0.51  0.80  0.82  0.72  0.66   
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stabilization from three hydrogen bonding interactions shown in appendix (Figure B-1a). 
3 can form a diverse network of intermolecular hydrogen bonds (Figure 3-8a) in which 
the Asn148 -NH2 group interacts with the -OCH3, while the N atom of His75 accepts two 
hydrogen bonds from HN and HN′. Electrostatic interactions with His75, Asn148, Thr150, 
and Gln168 also contribute to the stability of 3. IFD indicated that (Phe153 - 0.65; Å 
Phe164 - 0.55 Å) experienced the most significant changes with the corresponding side 
chain rmsd deviations compared to the apo structure (Table 3-2). 
N -methyl N -hydroxyurea (4):  Methyl hydroxyurea has two hydrogen bond donors and 
two acceptors. 4 produced a nitroxide radical intermediate and had the highest rate constant 
among the HUAs while interacting with Hb.
88
 However, it failed to form NO due to the 
missing -NHOH group.
146
 Similar to 3, IFD resulted in 80 poses for 4 but did not produce 
pose A or pose B and is not expected to interact with catalase CpdI to form C-ntroso 
formamide. The major cluster retained 36 docked poses that closely resembled pose A 
(Figure B-1b), but failed to hydrogen bond with the oxoferryl unit. In this cluster, a slightly 
modified network of hydrogen bonds existed, in comparison to pose A; here, the interaction 
of the oxoferryl oxygen with HN′ is replaced by HN′-   4 had a slightly larger Lipophilic 
EvdW contribution than 1 due to the interaction between the methyl group present on the 
NO with Pro129, Phe153, and Phe154. 4's electrostatic stabilization resulted from 
interaction with Gln168, Asn148, and His75. Only (Val116 - 1.36Å) experienced 
substantial structural changes in comparison to the apo structure (Table 3-2).  
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Figure 3-7: 2D interaction energy diagram depicting the per residue interactions between 
pose A and pose B conformations of hydroxyurea analogs 1, 5, 6 and 8 with catalase 
CpdI active site residues. The legend representing the various symbols are presented in 
Figure 8. 
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Figure 3-8: 2D interaction diagram depicting the per residue interactions for hydroxyurea 
analogs 3, 4 and 7 with catalase CpdI active site residues are shown in a, b and c. The 
legend here represents the type of amino acid residues and the diferent interactions they 
form. 
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Figure 3-8B: Predicted binding orientations of HUAs 3, and 4 pose conformations in 
catalase CpdI. 
N' -phenyl N -hydroxyurea (5): HUA 5 (1-hydroxy-3-phenylurea) has three hydrogen 
bond donors and two acceptors. It efciently released NO upon interacting with hemoglobin 
and was found to have the second highest rate after 4.
88
  Subsequently, we attributed, this to 
the transition state stabilization of the nitroxide radical caused by the  HN' hydrogen bonding 
to the Gly25 -C=O moiety along with strong hydrophobic interactions within hemoglobin's 
hydrophobic cavity.
146
 IFD produced 55 orientations and after clustering, pose A was 
dominant with 18 docked poses, while pose B had only 9 (Figure 3-9). Pose A had a better 
binding affinity compared to pose B with respect to hydrogen bonding and the 
LipophilicEvdW XP descriptors (Table 3-1). Furthermore, the phenyl group in 5 (pose A, 
Figure 3-7c) possessed a     stacking interaction with Phe153. This contributed to the 
large LipophilicEvdW score compared to pose B. Also, LipophilicEvdW interactions 
between the phenyl group of 5 and Val74, Phe153, Phe161, Ile165, and Phe164 were 
responsible for additional stabilization. IFD resulted in (Phe161 - 2.73Å and Ile165 - 0.70Å) 
(Table 3-2) experiencing significant structural rearrangement compared to the apo form. 
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Pose B (Figure 3-7d) was ranked third upon clustering, and had a significant 
LipophilicEvdW contribution due to the phenyl moiety interacting with Val74, Phe153, 
Ile155, Phe161, Ile165, and Phe164. The residues that underwent substantial changes in 
pose B were Val74, Val116, Phe161, and Gln168. The side chain rmsd deviations were in 
the range of (0.04 - 2.79Å) when compared to the apo structure of catalase CpdI (Table 3-
2).  
 
 
Figure 3-9: Predicted a)pose A and b)pose B binding orientations of 5 in catalase CpdI. 
N' -n-butyl N -hydroxyurea (6): This derivative is commonly known as 1-butyl-3-
hydroxyurea with three sites for hydrogen bond donation and two acceptors. IFD produced 
110 total poses. Clustering resulted in 20 pose A structures (Figure 3-7e) and 58 for pose B 
(Figure 3-7f). Pose B was predicted to have slightly better binding affinity compared to pose 
A. They had similar hydrogen bonding and LipophilicEvdW contributions as described by 
the XP descriptors (Table 3-1). Furthermore, in the pose B orientation both HN and HN′ were 
hydrogen bonded to the CpdI Fe=O moiety, whereas in pose A only the HN′ was hydrogen 
bonded to Fe=O. Both orientations had an XP RotPenal of 1.37 kcal mol-1, which is a 
 64 
 
rotational penalty due to constricting the ﬂexible n-butyl chain of 6 in the hydrophobic 
pocket. During IFD, the residues that experienced significant side chain movement for 
poseA were (Phe161 - 2.94Å Ile165 - 0.93Å and Gln168 - 0.51Å) while (Phe153 - 2.24Å 
Phe161 - 1.37Å and Gln168 - 0.80Å) moved most in pose B (Table 3-2).  
N', N'-diethyl N-hydroxyurea (7): This analog is known as 1,1-diethyl 3-hydroxyurea and 
consists of two donors and two acceptors for hydrogen bonding. 7 was the only HUA that 
did not produce NO despite having an -NHOH group in Hb.
88
 Our previous ﬂexible docking 
studies, determined that 7's inability to form NO was attributed to the absence of the HN′  
atom.
146
 However, this analog may interact with catalase CpdI to produce NO as it contains 
the essential -NHOH moiety required to form the C- nitroso formamide intermediate. IFD 
resulted in 22 binding conformations, however, 7 did not form even a single pose A 
confirmation. Clustering produced pose B (Figure 3-8c) as the preferred binding pose with 
16 docked structures. Substrate 7 has a major XP penalty 2.4 kcal mol-1 coming from the 
desolvation of the polar N' atom in a hydrophobic protein environment devoid of any 
hydrogen bonding (Table 3-1). IFD results indicated that residues (Phe161 - 2.91Å Ile165 - 
0.96Å and Gln168 - 0.82Å) experienced considerable side-chain movement (Table 3-2). 
N' -4-methoxy phenyl N -hydroxyurea (8): HUA 8 (1-methoxy-3-phenylurea) contains 
three hydrogen bond donors and three acceptors. Despite this substrate having the potential 
to release NO while interacting with hemoglobin, experimental studies were not possible due 
to solubility issues.
88
  8 has the potential to interact with catalase CpdI to produce NO due to 
the presence of the -NHOH moiety. IFD yielded 60 poses as ranked by GlideXP scores. 
Clustering produced 17 docked poses for pose A (Figure 3-7g) and 25 for pose B (Figure 3-
7h). However, pose A had better predicted binding afnies in terms of hydrogen bonding by 
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 E (Hbond + PhobEn Hb) = -1.91 kcal mol
-1
 and LipophilicEvdW interactions (Table 3-1). 
Both poses possessed a favorable LipophilicEvdW contribution due to the interaction of the 
methoxyphenyl substituent with Val73, Val74, Phe153, Phe161, Phe164, and Ile165. 
However, pose A had better predicted LipophilicEvdW due to additional interactions of the 
methoxyphenyl group with Pro162. For both pose A and pose B, residues Phe153, Phe154, 
Phe161, and Gln168 experienced considerable induced fit efects with side chain rmsds in 
the range (0.04 - 3.18Å) compared to their apo structure (Table 3-2). 
3.4.2  Proposed mechanism of action  
The exact mechanism of the catalase catalyzed C-nitroso formamide formation from 
HUA's remains unclear. IFD combined with available structural, biochemical, and 
experimental studies revealed insight into the reaction mechanism.
123,137,149,150
 Upon careful 
examination of docking orientations for pose A and pose B, it was observed that His75 
could act as either an acid or base catalyst or provide stabilizing hydrogen bonds to the 
HUA anion radicals produced during the course of the reaction. We propose four possible 
reaction mechanisms for C-nitroso formamide generation (Figure 3-3) corresponding to 
both pose A and B. We hypothesize that the hydroxyurea conversion occurs by the 
reduction of catalase CpdI by either a His mediated or direct mechanism equivalent to 
H2O2,137,151 as the -NHOH moiety of HUA represents an isostere of H2O2.  
Pose A mechanism of actions  
For pose A, the His mediated mechanism (Figure 3-10, top) involves interaction 
of a HUA with catalase CpdI. This would quench the cation radical present on the 
porphyrin ring by decomposing the double bond of oxoferryl to the hydroxyl-ferryl unit 
(CpdII) via HN′ migration, forming a radical on N' (Figure 3-10, 2). 
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Figure 3-10: Proposed reaction mechanism for HUA interaction with catalase CpdI for 
pose A orientations. Reaction scheme involving His mediated mechanism of action and 
reaction scheme describing direct mechanism of action. 
This hydrogen migration from N' to the oxoferryl oxygen atom would be assisted 
by the stabilizing interactions derived from the strong networked intermolecular 
hydrogen bonds and hydrophobic pocket created by Val74, Val116, Pro129, Phe153, 
Phe154, Phe161, Phe164, and Ile165. We hypothesize the radical would be localized on 
the nitrogen rather than oxygen atom in HUAs during this process based on following. 
Firstly, nitrogen radicals are commonly observed as they are more electron deficient than 
carbon radicals. They also have similar stabilities to oxygen centered radicals due to 
substituent effects.45 Further, gas phase DFT calculations on 2 by Vrcek et al.
149
 showed 
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that N-centered radicals are frequently formed by hydrogen migrations. Calculated 
mulliken spin densities showed that an unpaired electron on 2 would likely be located at 
the O and NO atoms. It was previously shown using EPR, that O-centered radicals (2) 
are the result of 1's interaction with human Hb.
88
 Nevertheless, these were not observed 
in 1's interaction with catalase, illustrating the feasibility of other radical formations.
123
 
From previous computational and experimental studies
123,149,152
 its reasonable to expect 
competetion between the HN and HO for transfer to the N' radical. The transfer of the HN 
 HN′ is corroborated by the resonance stabilization gained by NO radical, due to the 
lone pair donation from the neighboring oxygen atom. In the subsequent step, the oxygen 
atom would be deprotonated to generate an oxyanion. This is supported by Vrcek et al.
149
 
who showed that 1 behaves as a hydroxamic acid with deprotonation occurring on the O-
center to produce an oxyanion. Hence, it is hypothesized that the His75   plays a 
catalytic role to abstract the HO to produce an oxyanion HUA radical moiety. Further, 
reduction potential studies indicated that an electron from the oxyanion gets transfered to 
metal ion oxidants.42 This observation indicates a negative charge on the oxygen moiety, 
which switches to the N' radical and then transfers the radical to      to form reduced 
     . Finally, the oxygen of the hydroxyl-ferryl moiety would abstract the His75   
proton yielding water, catalase (     ), and C-nitroso formamide. In the case of the direct 
mechanism (Figure 3-10), the initial step of the reaction is equivalent to its His mediated 
counterpart. However, in the second step HO would get abstracted by the hydroxyl-ferryl 
group instead of His75 to form an oxonium ion of CpdII (Figure 3-10). Later, similar to 
pose A His mediated mechanism, the oxyanion charge would be transfered to reduce 
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      to       catalase, with the oxonium ion leaving the active site as water along with 
C-nitroso formamide. 
Pose B mechanism of actions 
Figure 3-11: Proposed reaction mechanism for HUA interaction with catalase CpdI for 
pose B orientations. Reaction scheme involving His mediated mechanism of action and 
reaction scheme describing direct mechanism of action. 
 
In the pose B mechanism (Figure 11), all analogs except 3 and 4 retained the 
same array of intermolecular hydrogen bonds observed with the QM/MM optimized 
H2O2-catalase CpdI complex.
137
 These networked intermolecular hydrogen bonds were 
observed since the -NHOH moiety represents an isostere of H2O2. The pose B mechanisms 
would differ from pose A with respect to hydrogen abstraction by the oxoferryl moiety. 
Here, the oxoferryl would abstract the HN instead of HN′ to form CpdI and HU    radical 
without the intermediacy of N' radical HU intermediate observed in pose A mechanism. 
The His-mediated pose B mechanism is similar to pose A, except for the rearrangement of 
HN atom to generate HU    radical. The remainder of the mechanism mimics that of pose 
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A. Contrastingly, the pose B direct mechanism is significantly different. Following the 
HN′ abstraction, the N-centered nitroxide radical would have to reorient itself by rotation 
around the C-   bond to interact with hydroxy-ferryl moiety, leading to the formation of 
C-nitroso formamide. Q-Chem 4.0
144,145
 was used to perform a torsional study of the N-
hydroxyurea radical. The torsional optimization (O-  -C-N') was performed using 
B3LYP/6-31G with a grid consisting of 75 radical shells and 302 angular points. The 
torsion was constrained in 15° increments ranging from -180° to 180°. The torsional 
profile rotating around the C-   bond (Figure B-5) showed a large rotational energy 
barrier of 21.54 kcal       (Table 3-3). Due to this penalty, we conclude the pose B 
direct mechanism would be unlikely to occur. However, if the reaction proceeds crossing 
this high energy barrier, the reorientation will result in a sequence of    radical mediated 
reactions.  First breaking the hydroxyl group of HU into radicals leading to the formation 
of C-nitroso formamide and    radical. Later the    radical induced another radical 
formation by breaking hydroxy ferryl moiety to form water and catalase.  
3.4.3 IFD dockings incorporating prime minimization  
Based on the  -  angles of the amino acid backbone, the side-chain rotamer 
library
143
 defines the most likely rotamer conformation based on its statistical occurrence 
in the PDB. However, the correct states are less clear to the presence of water, 
neighboring substrates, and co-factors. To account for the effect of co-factors like CpdI 
and understand the effect of small molecules like 1 in the side chain movements, we have 
also carried out IFD dockings using prime minimization. 
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Table 3-3. B3LYP/6-31G  DFT study of the torsional potentials for N-hydroxyurea 
radical.  
HU 
Radical 
Torsion  
Energy   
kcal mol
-1
   
-180  0.00   
-165  0.88   
-150  3.48   
-135  7.37   
-120  11.71   
-105  15.46   
-90  17.66   
-75  17.79   
-60  16.50   
-45  14.86   
-30  13.71   
-15  13.61   
0  14.92   
15  17.73   
30  21.54   
45  14.86   
60  16.50   
75  17.79   
90  17.66   
105  15.46   
120  11.71   
135  7.37   
150  3.48   
165  0.88   
180  0.00   
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IFD prime minimization dockings produced only pose B orientations for 1, 5, 6, 7, 
and 8. Only 5 produced the pose A orientation, however, pose B resulted in a lower 
energy conformation. These results indicate that pose B is the most likely pose (Table 3-
4).  
Table 3-4. Summary of IFD prime minimization orientations (# corresponds to number 
of) 
HUA  Gscore  Top 
pose  
# binding poses  # Hydrogen bonds   
kcal mol
-1
  Total  pose A  pose B  acceptors  donors   
1  -6.334  B  58  0  35  2  3   
2  NA  NA  NA  NA  NA  2  2   
3  -4.888  NA  79  NA  NA  2  2   
4  -5.469  NA  62  NA  NA  2  2   
5  -6.483  B  32  3  1  2  3   
6  -5.872  B  66  0  30  2  3   
7  -1.836  B  19  0  9  2  2   
8  -6.889  B  30  0  6  3  3   
 
3.4.4 Insights into the most likely mechanism of action.  
IFD results have revealed four possible reaction mechanisms (Figure 10 and 11) 
for HUAs; arising from pose A and pose B orientations. ProBiS,
103-105
 a web-based 
binding site prediction and analysis tool (consisting of 31,198 non-redundant protein 
structures) was used to scan existing heme-based enzymes. Results showed that the 
catalase CpdI active site framework is unique. It failed to identify a single heme-based 
protein with similar physiochemical properties to catalase CpdI, hence a singular 
mechanism of action with HUAs is likely.  
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During the examination of pose A and B for all HUAs, it was determined that 7 
could form only the pose B orientation. This can be attributed to the absence of the HN′ 
atom. We were curious to the reason, that why 7 failed to generate even a single 
confirmation looks like or close to pose A orientation even though HN′ hydrogen bonding 
is missing. We started to analyze if the rationale was due to sterics or the lack of HN′ as 7 
failed to form any orientation close to pose A. To identify the underlying cause, modified 
analogs of 6 (Figure B-2) were generated, in which the HN′ was replaced with -CH3 (6a) 
to create less sterically hindered structure. In the second analog we replaced the -NHN′ 
with a -CH2 group (6b) to study the importance of a polar HN′. IFD studies with 6a and 
6b revealed that pose B is dominant. However, unlike 7 "Pose A like" confirmations 
(Figure B-3), similar to pose A except for the HN′ hydrogen bonding interaction with the 
oxoferryl moiety (Table 3-1A) were generated for 6a and 6b. Results from these analysis 
clearly show that 7's inability to form pose A like confirmation is a consequence of 
sterical clashes.  
Moreover, results suggest that 6a, 6b, and 7 would interact with catalase CpdI to 
produce NO as they contain the critical -NHOH group. This hypothesis is supported by 
the interaction of hydroxylamine (NH2OH) with catalase CpdI to produce HNO.
150
 
Considering that hydroxylamine produces HNO without an HN′ atom or amide functional 
group, small molecules with an -NHOH moiety should be adequate to produce HNO. In 
fact, hydroxylamine was shown to have a similar reaction profile to 1 when interacting 
with catalase CpdI to produce HNO, as confirmed by EPR spectra.
150
 Later, the reductive 
nitrosylation of ferric catalase by HNO produces the ferrous catalase-NO complex, an NO  
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source (Figure B-4). To examine this in more detail we docked (with IFD) 
hydroxylamine; this resulted only in pose B orientations.  
Interestingly, the oxidation mechanisms of hydroxylamine
150
 and H2O2
137
 with 
catalase should be very similar, again because they are isosteres. Overall, IFD results 
conclude that, even though 6a and 6b produce pose A like confirmation, 6a, 6b and 7 
cannot adopt the pose A mechanism of action (Figure 10) due to the absence of the N' 
preventing them to form C-nitroso formamide. Previous spectroscopic and biochemical 
studies along with current IFD results show that biosynthetic production of NO, from 
possibly all HUAs, would occur predominantly via pose B orientations. Experimental 
EPR and kinetics studies of these modified analogs with catalase would confirm proposed 
reaction mechanisms (i.e. that pose B mechanism is dominant). Further, QM/MM studies 
are underway to shed more light onto NO production via HUAs, interacting with heme-
based enzymes. 
3.5 Conclusions  
The pharmacological efficacies of hydroxyurea therapy result from NO donation 
causing the elevation of fetal Hb levels and vasodilation production preventing sickle cell 
adhesion to endothelium cells. Catalase CpdI is an enzyme known to produce NO upon 
interacting with HU; however, binding and mechanistic details remain unkown. Presently, 
we examined nine hydroxyurea analogs (HUAs), including modified analogs complexed 
with catalase CpdI using induced fit docking (IFD) coupled with scoring function 
decomposition. Our work revealed an important network of intermolecular hydrogen 
bonds created by distal residues His75, Asn148, Gln168, and oxoferryl-heme to HUAs. 
Also, strong hydrophobic interactions were conferred to substrates by the active site 
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residues Val73, Val74, Val116, Phe153, Phe161,Pro162, Phe164, and Ile165. Further, 
Phe161 was identified to undergoes significant induced fit effects to accommodate 
aromatic substrates like 5 and 8. We proposed reaction mechanisms using information 
obtained from predicted binding modes coupled with available biochemical data.  
Bioinfromatics results, obtained via binding site analysis (i.e ProBiS) indicated 
that catalase CpdI could have a unique mechanism of action compared to nearly all heme-
based enzymes. Moreover, the similarities in structural, physiochemical, and biological 
action between hydroxyurea, hydroxylamine, and hydrogen peroxide confirms the 
likelihood of the pose B His-mediated pathway due to a high rotational energy barrier that 
is required in the direct mechanism. Further analysis of the 6a, 6b, and 7 docking poses 
suggested that pose B is favored due to accommodation of bulky substituents and 
avoidance of sterical clashes. These dockings along with the hydroxylamine biochemical 
data show that a -NHOH moiety, an isostere to H2O2, is necessary to produce NO and will 
most likely occur via the pose B His-mediated mechanism. Structural and mechanistic 
details of HUAs and catalase CpdI should serve as a model for continued structure based 
drug design, specifically targeting new scaffolds with -NHOH as the pose pharmacaphore.  
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Chapter 4: Computational correlation studies towards inactivation 
of O
6
- alkylguanine-DNA alkyltransferase by O
6
-benzylguanine 
analogs 
Note to the Reader 
Portions of this chapter comprising my computational work has been previously 
published as Pauly, G.T.; Loktionova, N. A.; Fang, Q.; Vankayala, S. L.; Guida, W. C.; 
Pegg, A. E.     Substitution of aminomethyl at the meta-position enhances the inactivation 
of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. J.Med. 
Chem. 2008, 51, 7144-7153. Copyright © 2013 American Chemical Society.  doi: 
10.1021/jm800675p.  PMID:18973327 
Author contributions. SLV and WCG designed the computational research; SLV 
performed research, analyzed data and wrote the initial draft; WCG improvised the draft. 
 
4.1 Abstract 
The main forms of cancer treatment are Chemotherapy and Radiation therapy. As 
part of chemotherapy, various alkylating agents are used to induce DNA damage. Most of 
these alkyl lesions are mutagenic and can be highly cytotoxic as secondary effects. 
Eventually cells have evolved with various mechanisms to detect and repair DNA 
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damage, resulting in therapeutic resistance.  O
6
-alkylguanine-DNA alkyltransferase 
(AGT) is a DNA repair protein that acts in a single step to restore DNA with O
6
-
Alkylguanine lesions, and thus prevents mutations and apoptosis arising from alkylated 
guanines.  A novel strategy has been explored to reverse this drug resistance by inhibiting 
the DNA repair pathways to enhance chemo and radio sensitivity.  So various analogs of 
benzyl guanine were synthesized and tested for activity as potential inhibitors of AGT. 
The nature and position of the substitutions involving methyl and aminomethyl groups 
profoundly affected their activity. Molecular modeling studies of their interactions with 
alkyltransferase provided a molecular explanation for these results. The square of the 
correlation coefficient (R
2
) obtained between E-model scores (obtained from GLIDE 
XP/QPLD docking calculations) vs. log(IC50) values via a linear regression analysis was 
0.95. The models indicate that the ortho- substitution causes a steric clash interfering 
with binding whereas the meta- aminomethyl substitution allows an interaction of the 
amino group to generate an additional hydrogen bond with the protein for its enhanced 
activity. Virtual screening using NCI diversity set 2 against this AGT protein model lead 
to the discovery 7 novel lead molecules.  
4.2 Introduction 
O
6
-Alkylguanine-DNA alkyltransferase is a unique DNA repair protein that acts 
in a single step to restore DNA with O
6
-alkylguanine adducts by transferring the alkyl 
group to an acceptor site, which in human alkyltransferase is located at Cys145.
153-155
 
Alkyltransferase activity in tumors is an important source of resistance to therapeutic 
alkylating agents such as dacarbazine, temozolomide, 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU) or 1-(2-chloroethyl)-3-(trans-4-
 
methylcyclohexyl)-1-
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nitrosourea.
153,154,156-160
 O
6
-Benzylguanine has been shown to be a potent inhibitor of 
human alkyltransferase. O
6
-Benzylguanine acts as a pseudosubstrate. After binding in the 
active site, it leads to the formation of S-benzylcysteine at the Cys145 acceptor site 
irreversibly inactivating the protein.
161-163
 A related compound O
6
-(4-
bromothenyl)guanine was found to be a slightly more potent inactivator of 
alkyltransferase
164
 and is thought to act in the same way. Both compounds are undergoing 
clinical trials.
156,159,160,165-170
 Although there have been some responses in these trials 
providing proof of concept for the target, it is clear that improved inhibitors will be 
needed.  
 
Figure 4-1: Direct reversal pathway repairing DNA damage by reversing the alkylation 
on O
6
-guanine.  
Since the original development of O
6
-benzylguanine, structural and biochemical 
studies have provided a much greater understanding of the repair reaction catalyzed by 
alkyltransferase and the binding and reaction of this inhibitor. After binding the substrate 
DNA via the minor groove using a helix-turn-helix motif, the alkyltransferase protein 
brings about a change in the DNA structure which rotates the alkylated guanine 
deoxynucleoside from the base stack into an active site pocket which contains the Cys145 
acceptor residue.
155,171
 This places the O
6
-alkylguanine in the correct position for repair 
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in a hydrophobic cleft where the Cys145 and Val148 carbonyls accept hydrogen bonds 
from the exocyclic amine of the guanine, the N of Ser159 donates a hydrogen bond to the 
substrate guanine-O
6
, and the hydroxyl of Tyr114 donates hydrogen bonds to guanine-N3 
(Figure 4-1). These interactions exactly position the alkyl group for attack by Cys145. 
This residue is highly reactive by virtue of its activation to a thiolate anion by a 
Glu172:His146:water:Cys145 hydrogen bond network.
155,163,172
 O
6
-Benzylguanine binds 
much more weakly at the active site pocket since all of the interactions with the 
alkyltransferase-DNA binding domain are lost but it is held in a position that allows 
attack by Cys145 via the interactions with the guanine moiety described above and the 
interaction of the benzyl group with the side-chain of Pro140.
155,163
 Mutation of this Pro 
residue profoundly reduces the ability of O
6
-benzylguanine to inactivate human 
alkyltransferase.
173,174
 Despite the weak binding, the reactivity of benzyl in bimolecular 
displacement reactions such as that occurring in the alkyltransferase active site facilitates 
the inactivating reaction. However, the rate constant for the reaction with O
6
-
benzylguanine free base is only c. 600 M
-1
. sec
-1
,
162
 which is >10,000 times less than that 
for the repair of O
6
-methylguanine in DNA and or of oligodeoxyribonucleotides 
containing O
6
-benzylguanine, which are much more potent inactivators.
175,176
 Such 
oligodeoxyribonucleotides are not ideal for clinical use and other attempts to improve the 
binding of low M.W. pseudosubstrates are needed. 
We have now undertaken in silico screening of three O
6
-
[(aminomethyl)benzyl]guanines (compounds 1- 3) and three O
6
-(methylbenzyl)guanines 
(compounds 5-7) shown in Figure 4-2. It was found that the nature and position of the 
substitution profoundly affected the ability to inactivate human alkyltransferase. 
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Molecular modelling studies using one of the crystal structures available for the protein 
and its interaction with compounds 1-3, 5-7 and O
6
-benzylguanine were carried out and 
provide a plausible explanation for these results and show that the meta-substituent on 
O
6
-[3-(aminomethyl)benzyl]guanine (2) provides additional interactions with the active 
site pocket that increase the affinity for O
6
-benzylguanine derivatives and generates a 
more potent and soluble alkyltransferase inhibitor. Later, with the successful prediction 
of relative binding affinities, we further used the model to unveil novel lead molecule by 
virtual screening studies using NCI diversity set2 followed by biological testing.  
               
Figure 4-2:  Substituted O
6
-benzylguanines and an N
6
-[(hydroxymethyl)benzyl]-2-
aminoadenine resulting from a rearrangement of 3. 
4.3 Methods 
The computational modeling studies relied upon the GLIDE (Grid-based Ligand 
Docking from Energetics) program (Glide, version 4.5, Schrödinger, LLC New York, NY 
2007)
177-179
 for the docking simulations. These simulations were performed using the X-
ray crystal structure of the human alkyltransferase bound to a DNA oligonucleotide and 
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containing O
6
-methylguanine determined at 3.2 Å resolution (PDB ID:1T38).
171,180
 For 
our studies, DNA was removed except for O
6
-methylguanine, see Figure 4-3. Solvent 
molecules in the protein crystal structure were deleted, except for a water molecule in the 
active site (WAT 1), and the protein was then prepared for the docking studies by 
processing it using Schrödinger’s protein preparation facility. This procedure minimizes 
the protein to 0.30 Å RMSD using the OPLS-2001 force field. Later the protein/ligand 
complex was taken and pursued Macromodel Mixed torsional /Low-mode sampling 
conformational search (MacroModel, version 9.5, Schrödinger, LLC, New York, NY, 
2007). This procedure employed OPLS 2001 force field, with a distance-dependent 
electrostatic  treatment with 2.0 units of dilectric constant. 
 
Figure 4-3: Prepared protein of the human alkyltransferase without DNA.  O
6
-
methylguanine and WAT1 also shown. 
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A 5Å shell of residues around the native ligand and water molecule were allowed 
to undergo energy minimization. Later ASN 157 and ARG 135 residues along with the 
rest of the protein residues were frozen for the conformational search. The ligand was 
allowed to translate and rotate in the active site and generated 892 conformers.  
The lowest energy conformer that retained the native ligand pose in the X-ray 
crystal structure of PDB 1T38 was carried for further studies. O
6
-Methylguanine, O
6
-
benzylguanine and the O
6
-benzylguanine derivatives were prepared using Schrodinger’s 
LigPrep facility. The initial docking studies were done with GLIDE (version 4.5, 
Schrödinger, LLC, New York, NY, 2007) operating in either SP or XP mode.
177-179
 
Maestro, version 8.0, Schrödinger Suite 2007, LLC New York, NY 2007) was employed 
as the graphical user interface and for generation of the graphics used in the figures. The 
best docked structure were chosen using the Glide_gscore function (Glide Score). For 
enhanced docking accuracy the best docked structures from XP were used to calculate the 
ligand partial charges and then redocked using Schrödinger’s QPLD (Quantum Polarized 
Ligand Docking) method. In order to validate the docking approach, self docking was 
performed using the partial native ligand O
6
-methylguanine using XP/QPLD. The RMS 
of the docked pose when compared to the crystallographically observed position was 0.14 
Å, and thus GLIDE produced a docking mode that closely resembled the X-ray crystal 
structure.  
4.4 Results and Discussion 
Computational docking studies were performed using the GLIDE program 
(version 4.5, Schrödinger, LLC, New York, NY, 2007). The docked structures were 
chosen for comparison with experimentally determined EC50 values using either the 
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Glide Score or Emodel scoring function. For enhanced docking accuracy the best docked 
structures using GLIDE extra precision (XP) mode were used to calculate ligand partial 
charges in the protein environment and then redocked with XP using Schrödinger’s 
QPLD (Quantum Polarized Ligand Docking) method.
181
 The Maestro user interface, 
(version 8.0, Schrödinger, LLC, New York, NY, 2007) was employed to set up the 
GLIDE docking studies and for visualization of the results. The AGT X-ray crystal 
structure chosen for our modeling studies was human alkyltransferase bound to DNA 
containing O
6
-methylguanine and Cys145 mutated to serine to prevent the alkylation 
reaction from taking place.
171
 In our modeling studies, Ser145 was mutated back to 
cysteine. To validate the docking approach, self-docking was performed with XP/QPLD 
using the partial native ligand: O
6
-methylguanine. The RMS of the docked pose when 
compared to the crystallographically observed position of the O
6
-methylguanine moiety 
was 0.14 Å, and thus GLIDE produced a docking mode that closely resembled the X-ray 
crystal structure. Thus, our hypothesis was that GLIDE would be capable of producing 
docking poses for the compounds studied that are similar to the position, orientation and 
conformation adopted by the ligands prior to nucleophilic attack by Cys145 and that the 
docking scores obtained would correlate well with the experimentally observed ED50 
values for enzyme inactivation. Although there is a crystal structure available for human 
alkyltransferase benzylated at Cys145.
163
 this structure was not employed to model the 
O
6
-benzylguanine analogs described in this study since the GLIDE program is unsuitable 
for modeling covalent bonds formed between the ligand and protein. 
In addition to O
6
-methylguanine, compounds 1-3, 5-7 and O
6
-benzylguanine were 
docked to human alkyltransferase using the GLIDE XP. Each pose of these compounds 
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was redocked with XP using the QPLD method. The coefficient of determination (i.e., 
the square of the correlation coefficient, R
2
) was calculated between QPLD Glide Scores 
vs. log(ED50) values, determined in the presence of DNA, as part of a linear regression 
analysis. An acceptable R
2
 value of 0.86 between log(ED50) values and XP/QPLD Glide 
Scores was obtained (Figure 4-4). 
Emodel scores were also used for correlation studies. It had been previously 
observed by Bytheway and Cohran
182
 that Emodel scores correlated better with log(ED50) 
values than Glide Scores in their particular study. In our study, the coefficient of 
determination obtained between E-Model scores (obtained from XP/QPLD calculations) 
vs. log(ED50) values via a linear regression analysis gave an exceptional R
2
 of 0.96, 
shown in Figure 4-5. It is noteworthy that Emodel is a composite scoring function, 
derived from a combination of the Glide Score itself coupled with Coulombic energy, van 
der Waals energy, and ligand strain energy terms, and is used by GLIDE to select the best 
docking pose for each individual inhibitor regardless of the scoring function subsequently 
used and to rank order the inhibitors. Emodel scores were also used for correlation 
studies. It had been previously observed by Bytheway and Cohran
182
 that Emodel scores 
correlated better with Log(ED50) values than Glide Scores in their particular study. In our 
study, the correlation coefficient obtained between Emodel (obtained from XP/QPLD 
calculations) vs. Log(ED50) via a linear regression analysis gave an exceptional 
correlation coefficient of 0.99, shown in Figure 4-5. It is noteworthy that Emodel is a 
composite scoring function, derived from a combination of the Glide Score itself coupled 
with Coulombic energy, van der Waals energy, and ligand strain energy terms, and is 
used to both select the best docking pose for each inhibitor and rank order the inhibitors.  
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Figure 4-4:  Plot of log(ED50) values versus QPLD_Glide_scores. Numbering 
corresponds to compounds listed in Table 3. The ED50 values determined in the presence 
of DNA from Table 2 were used. 
 
Figure 4-5: Plot of log(ED50) values versus E-Model scores. Numbering corresponds to 
compounds listed in Table3. The ED50 values determined in the presence of DNA from 
Table 2 were used. 
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From examination of the QPLD based docking modes, one can conclude that the 
binding affinities correlate quite well with the number of hydrogen bonds and good van 
der Waals contacts formed between the inhibitor and the alkyltransferase binding site. 
There is insufficient space to adequately accommodate the ortho substituted 
benzylguanines. Thus, due to fewer favorable van der Waals contacts and due to their 
fewer hydrogen bonds, compounds 3 and 7 are the least potent of the inhibitors we tested 
in the present study. On the other hand, compounds 1 and 2 exhibit four and three 
hydrogen bonds respectively and both form good van der Waals contacts with the 
receptor. The main reasons for enhanced effectiveness compared to other analogs. 
Further, the ortho analogs have the lowest hydrogen bonds. All the values of these 
parameters are summarized in Table 2. 
Table 4-2. Docking parameters derived from docking compounds 1-3, 5-7, O
6
-
benzylguanine and O
6-
methylguanine to human alkyltransferase. 
Compound Inhibitor E-model Glide H-bonds Good  
Number   Score Score  vdw  
     Contacts  
2 O6-[3-(aminomethyl)benzyl]guanine -88.1 -9.42 4 297  
1 O6-[4-(aminomethyl)benzyl]guanine -82.0 -9.46 3 312  
5 O6-[4-(methyl)benzyl]guanine -81.5 -9.54 3 306  
 O6-benzylguanine -78.2 -8.79 3 287  
6 O6-[3-(methyl)benzyl]guanine -77.5 -9.30 3 289  
 O6-methylguanine -56.6 -7.16 4 177  
3 O6-[2-(aminomethyl)benzyl]guanine -52.2 -6.75 2 260  
7 O6-[2-(methyl)benzyl]guanine -52.0 -6.12 1 180  
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Figure 4-6 shows the key hydrogen bonding interactions of compound 2 with 
human alkyltransferase. Interactions with residues Tyr114, Cys145, Ser159 and Asn137 
are seen. (All except for the interaction with Tyr114 involve interaction with protein 
backbone rather than the amino acid side chains.)  
 
Figure 4-6: The key hydrogen bonding interactions of compound 2 (O
6
-[3-
(aminomethyl)benzyl]guanine) with the protein residues represented in stick model. The 
inhibitor is represented in green for carbon, blue for nitrogen and red for oxygen. The rest 
of the protein as pale green ribbon cartoon.  
 
Figure 4-7 shows an overlay of all of the inhibitor poses in the active site with O
6
-
methylguanine. It is clearly apparent that compounds 3 and 7 are not oriented in the 
catalytic site of human alkyltransferase in same way as the other inhibitors. Having 
obtained a co-efficient of determination close to 0.96 and visual inspection of all the 
analogs clearly validated our model by accurately predicting weak inhibitor capabilities 
of ortho substituents. Further, we used this AGT model to virtually screen the NCI 
Diversity Set 2 consisting of 1880 small molecules. After the virtual screening using the 
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GlideXP scoring function we retained the top 50 molecules and they were tested for 
biological activity by Dr. Natalia A Loktionova, and Dr. Sreenivas. We found 7 novel 
lead compounds that caused the following % of AGT activity to remain  at 200 μM of 
these small molecule concentrations (Figure 4-8). 
 
Figure 4-7: Overlay of the position of all of the docked compounds in the human 
alkyltransferase active site with the native ligand O
6
-methylguanine and parent inhibitor 
O
6
-benzylguanine. All of the potent inhibitor poses (compounds 1, 2, 5, 6 and O
6
-
benzylguanine) in green are oriented in the same way as the native ligand O
6
-
methylguanine. The ineffective inhibitors O
6
-[2-(aminomethyl)benzyl]guanine (3) in red 
and O
6
-[2-(methyl)benzyl]guanine (7) in yellow are not oriented in the same way as O
6
-
methylguanine. The rest of the color code is the same as Fig 4. 
We found an interesting observation that our virtual screening studies identified 
NSC 45383 to be streptonigrin, an aminoquinone known to have antitumour and 
antibacterial properties. Moreover, this compound functions through DNA inhibition, and 
induces DNA strand breaks, however, the target enzyme is not known till date. Hence our 
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model helped identify an already existing inhibitor and identified AGT as its target 
(Figure 4-9). 
 
Figure 4-8: AGT activity remaining (%) at 200 uM of the following NSC drugs 
4.5 Conclusion 
The addition of a meta aminomethyl group to O
6
-benzylguanine forming compound 2 
results in an approximately 20-fold improvement in the ability to inactivate purified 
human alkyltransferase. This improvement is seen in assays conducted with or without 
added DNA. It is noteworthy that the molecular modeling studies showed a similar trend 
and an R
2
 of 0.90 (data not shown) for a linear regression analysis of log(ED50), 
determined in the absence of DNA, vs. XP/QPLD Glide Scores and an R
2 
of 0.98 (data 
not shown) for log(ED50), determined in the absence of DNA, vs. Emodel scores were 
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obtained. As previously noted, inactivation of alkyltransferase by O
6
-benzylguanine
183
 is 
enhanced 3-4 –fold by the presence of DNA, which stimulates the rate of alkyl 
transfer.
184
 
In contrast, some O
6
-benzylguanine derivatives with bulky substituents are much 
less potent inhibitors in the presence of DNA since they cannot be accommodated in the 
active site when DNA is bound there 
184,185
. The inactivation of alkyltransferase by 
compounds 1 and 2 was increased by the presence of DNA indicating that these 
compounds, like O
6
-benzylguanine, do not compete with DNA for access to the active 
site. However compound 1, the para aminomethyl- derivative did not show any 
improvement in inhibitory potency over O
6
-benzylguanine itself. These results are very 
well explained by the molecular modelling studies, which indicate the formation of an 
additional hydrogen bond when compound 2 is bound in the active site. The aminomethyl 
group from 2 but not 1 is able to interact with Asn137. This also explains why a simple 
methyl substitution (compound 6) was ineffective since it cannot form this bond. The 
modelling studies also show clearly why the ortho- substituted O
6
-benzylguanine 
derivatives (3 and 7) are much less effective (> 200-fold) than O
6
-benzylguanine since, 
due to steric clashes, they cannot be positioned in the same way as the parent compound. 
Our results not only demonstrate that 2 may be a valuable alkyltransferase 
inhibitor but they also show clearly the value of molecular modelling for the design of 
improved alkyltransferase inhibitors. The remarkable correlation coefficient obtained 
using XP/QPLD via E-Model and the compounds tested here shows that the available 
structures of human alkyltransferase can clearly be used for this process. The remarkable 
R
2
 values obtained using XP/QPLD with E-Model scoring for ranking the compounds 
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tested here shows that the structure of human alkyltransferase bound to DNA containing 
O
6
-methylguanine and Cys145 mutated to serine can clearly be used as a starting 
structure for this process. The mutation of Ser145 back to Cys, as is appropriate for the 
wild type enzyme, and refinement of the structure obtained with MacroModel was 
essential in order to obtain the R
2
 values we report.  
 
 
 
Figure 4-9: The key hydrogen bonding interactions of streptonigrin (NSC 45383) with the 
protein residues represented in stick model. The inhibitor is represented in brown for 
carbon, blue for nitrogen and red for oxygen. The rest of the protein as magneta ribbon 
cartoon. 
 
 91 
 
The model we have generated should be highly useful in the design of more potent 
inhibitors by performing additional modeling studies on O
6
-benzylguanine analogs and 
by virtually screening databases of commercially available compounds to identify 
potential new lead compounds for further elaboration. And we started with the GlideXP 
virtual screening studies of NCI Diversity set2 (NCId2) obtained from NIH to our AGT 
model produced more than 100 lead hits that can inhibit AGT. When our collaborators 
tested for their % of AGT biological activity remaining at 200 μM for all these 50 top 
scoring compounds, we identified 7 novel lead compounds. 
Interestingly, we observed that our studies discovered the NSC 45383 to be 
streptonigrin, an aminoquinone known to have antitumour and antibacterial properties 
(Figure 4-9). Until now the exact target is unknown, but our studies clearly showed that 
AGT remains as its prime target to inhibit DNA synthesis. As part of my future research, 
studies involves finding Lead molecules to inhibit AGT protien.   So presently  pursuing 
virtual screening  docking studies by docking large libraries of Zinc Leadlike compounds 
( around 1.8 million compounds) in the Global energy conformer of AGT 1T38 obtained 
through GlideXP virtual screening studies.  
 
4.6 Acknowledgments:  
I would like to thank my collaborators for their biological studies supporting this 
work, Dr. Natalia A Loktionova, Dr. Sreenivas and Dr. Anthony Pegg from The 
Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, 
Pennsylvania 17033. 
 
 92 
 
 
 
Bibliography  
1. Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S. H., Structure-based virtual 
screening for drug discovery: a problem-centric review. AAPS J 2012, 14, 133-141. 
2. Leeson, P., DRUG DISCOVERY Chemical beauty contest. Nature 2012, 481, 
455-456. 
3. C, B. R.; Subramanian, J.; Sharma, S. D., Managing protein flexibility in docking 
and its applications. Drug Discov Today 2009, 14, 394-400. 
4. Boehr, D. D.; Nussinov, R.; Wright, P. E., The role of dynamic conformational 
ensembles in biomolecular recognition. Nat Chem Biol 2009, 5, 789-796. 
5. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; 
Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T., Extra Precision Glide: Docking and 
Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. 
J. Med. Chem. 2006, 49, 6177-6196. 
6. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D., 
Improved protein-ligand docking using GOLD. Proteins-Structure Function and 
Genetics 2003, 52, 609-623. 
7. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. 
K.; Olson, A. J., Automated docking using a Lamarckian genetic algorithm and an 
empirical binding free energy function. Journal of Computational Chemistry 1998, 19, 
1639-1662. 
8. Kramer, B.; Rarey, M.; Lengauer, T., Evaluation of the FLEXX incremental 
construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241. 
9. Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C. R., Towards the 
development of universal, fast and highly accurate docking/scoring methods: a long way 
to go. British Journal of Pharmacology 2008, 153, S7-S26. 
10. Huang, S.-Y.; Grinter, S. Z.; Zou, X., Scoring functions and their evaluation 
methods for protein-ligand docking: recent advances and future directions. Phys. Chem. 
Chem. Phys. 2010, 12, 12899-12908. 
11. Meng, X. Y.; Zhang, H. X.; Mezei, M.; Cui, M., Molecular docking: a powerful 
approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011, 7, 146-
157. 
 93 
 
12. Moustakas, D. T.; Lang, P. T.; Pegg, S.; Pettersen, E.; Kuntz, I. D.; Brooijmans, 
N.; Rizzo, R. C., Development and validation of a modular, extensible docking program: 
DOCK 5. J Comput Aided Mol Des 2006, 20, 601-619. 
13. Raub, S.; Steffen, A.; Kamper, A.; Marian, C. M., AIScore chemically diverse 
empirical scoring function employing quantum chemical binding energies of hydrogen-
bonded complexes. J Chem Inf Model 2008, 48, 1492-1510. 
14. Sotriffer, C. A.; Sanschagrin, P.; Matter, H.; Klebe, G., SFCscore: scoring 
functions for affinity prediction of protein-ligand complexes. Proteins 2008, 73, 395-419. 
15. Bohm, H. J., LUDI: rule-based automatic design of new substituents for enzyme 
inhibitor leads. J Comput Aided Mol Des 1992, 6, 593-606. 
16. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P., 
Empirical scoring functions: I. The development of a fast empirical scoring function to 
estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 
1997, 11, 425-445. 
17. Xue, M.; Zheng, M.; Xiong, B.; Li, Y.; Jiang, H.; Shen, J., Knowledge-based 
scoring functions in drug design. 1. Developing a target-specific method for kinase-
ligand interactions. J Chem Inf Model 2010, 50, 1378-1386. 
18. Ishchenko, A. V.; Shakhnovich, E. I., SMall Molecule Growth 2001 
(SMoG2001): an improved knowledge-based scoring function for protein-ligand 
interactions. J Med Chem 2002, 45, 2770-2780. 
19. Muegge, I., PMF scoring revisited. J Med Chem 2006, 49, 5895-5902. 
20. Mooij, W. T.; Verdonk, M. L., General and targeted statistical potentials for 
protein-ligand interactions. Proteins 2005, 61, 272-287. 
21. Zhao, X.; Liu, X.; Wang, Y.; Chen, Z.; Kang, L.; Zhang, H.; Luo, X.; Zhu, W.; 
Chen, K.; Li, H.; Wang, X.; Jiang, H., An improved PMF scoring function for universally 
predicting the interactions of a ligand with protein, DNA, and RNA. J Chem Inf Model 
2008, 48, 1438-1447. 
22. Terp, G. E.; Johansen, B. N.; Christensen, I. T.; Jorgensen, F. S., A new concept 
for multidimensional selection of ligand conformations (MultiSelect) and 
multidimensional scoring (MultiScore) of protein-ligand binding affinities. J Med Chem 
2001, 44, 2333-2343. 
23. Wang, R. X.; Lai, L. H.; Wang, S. M., Further development and validation of 
empirical scoring functions for structure-based binding affinity prediction. Journal of 
Computer-Aided Molecular Design 2002, 16, 11-26. 
 94 
 
24. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B., Consensus 
scoring for ligand/protein interactions. J Mol Graph Model 2002, 20, 281-295. 
25. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J., Docking and scoring in 
virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 
2004, 3, 935-949. 
26. Meiler, J.; Baker, D., ROSETTALIGAND: Protein-small molecule docking with 
full side-chain flexibility. Proteins-Structure Function and Bioinformatics 2006, 65, 538-
548. 
27. Abagyan, R.; Totrov, M.; Kuznetsov, D., Icm - a New Method for Protein 
Modeling and Design - Applications to Docking and Structure Prediction from the 
Distorted Native Conformation. Journal of Computational Chemistry 1994, 15, 488-506. 
28. Clark, K. P.; Ajay, Flexible Ligand Docking without Parameter Adjustment 
across 4 Ligand-Receptor Complexes. Journal of Computational Chemistry 1995, 16, 
1210-1226. 
29. Morris, G. M.; Goodsell, D. S.; Huey, R.; Olson, A. J., Distributed automated 
docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. Journal of 
Computer-Aided Molecular Design 1996, 10, 293-304. 
30. Welch, W.; Ruppert, J.; Jain, A. N., Hammerhead: fast, fully automated docking 
of flexible ligands to protein binding sites. Chem Biol 1996, 3, 449-462. 
31. Totrov, M.; Abagyan, R., Flexible ligand docking to multiple receptor 
conformations: a practical alternative. Curr Opin Struct Biol 2008, 18, 178-184. 
32. Cavasotto, C. N.; Abagyan, R. A., Protein flexibility in ligand docking and virtual 
screening to protein kinases. J Mol Biol 2004, 337, 209-225. 
33. Jiang, F.; Kim, S. H., Soft Docking - Matching of Molecular-Surface Cubes. 
Journal of Molecular Biology 1991, 219, 79-102. 
34. Ferrari, A. M.; Wei, B. Q.; Costantino, L.; Shoichet, B. K., Soft docking and 
multiple receptor conformations in virtual screening. J Med Chem 2004, 47, 5076-5084. 
35. Leach, A. R., Ligand docking to proteins with discrete side-chain flexibility. 
Journal of Molecular Biology 1994, 235, 345-356. 
36. Kolossvary, I.; Guida, W. C., Low-mode conformational search elucidated: 
application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP. J. 
Comput. Chem. 1999, 20, 1671-1684. 
 95 
 
37. Alberts, I. L.; Todorov, N. P.; Dean, P. M., Receptor flexibility in de novo ligand 
design and docking. J Med Chem 2005, 48, 6585-6596. 
38. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, 
D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated docking with selective 
receptor flexibility. Journal of Computational Chemistry 2009, 30, 2785-2791. 
39. Taylor, R. D.; Jewsbury, P. J.; Essex, J. W., FDS: flexible ligand and receptor 
docking with a continuum solvent model and soft-core energy function. Journal of 
Computational Chemistry 2003, 24, 1637-1656. 
40. Carlson, H. A., Protein flexibility and drug design: how to hit a moving target. 
Curr Opin Chem Biol 2002, 6, 447-452. 
41. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R., Four-dimensional docking: 
a fast and accurate account of discrete receptor flexibility in ligand docking. J Med Chem 
2009, 52, 397-406. 
42. Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T., FlexE: efficient molecular 
docking considering protein structure variations. Journal of Molecular Biology 2001, 
308, 377-395. 
43. Knegtel, R. M.; Wagener, M., Efficacy and selectivity in flexible database 
docking. Proteins 1999, 37, 334-345. 
44. Najmanovich, R.; Kuttner, J.; Sobolev, V.; Edelman, M., Side-chain flexibility in 
proteins upon ligand binding. Proteins-Structure Function and Genetics 2000, 39, 261-
268. 
45. Sherman, W.; Beard, H. S.; Farid, R., Use of an induced fit receptor structure in 
virtual screening. Chem. Biol. Drug Des. 2006, 67, 83-84. 
46. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R., Novel 
Procedure for Modeling Ligand/Receptor Induced Fit Effects. J. Med. Chem. 2006, 49, 
534-553. 
47. Wagener, M.; Vlieg, J. D.; Nabuurs, S. B., Flexible protein-ligand docking using 
the Fleksy protocol. J Comput Chem 2012. 
48. Jacobson, M. P.; Friesner, R. A.; Xiang, Z.; Honig, B., On the Role of the Crystal 
Environment in Determining Protein Side-chain Conformations. J. Mol. Biol. 2002, 320, 
597-608. 
49. Jacobson, M. P.; Kaminski, G. A.; Friesner, R. A.; Rapp, C. S., Force Field 
Validation Using Protein Side Chain Prediction. J. Phys. Chem. B 2002, 106, 11673-
11680. 
 96 
 
50. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R., A new method for ligand 
docking to flexible receptors by dual alanine scanning and refinement (SCARE). J 
Comput Aided Mol Des 2008, 22, 311-325. 
51. Koska, J.; Spassov, V. Z.; Maynard, A. J.; Yan, L.; Austin, N.; Flook, P. K.; 
Venkatachalam, C. M., Fully Automated Molecular Mechanics Based Induced Fit 
Protein-Ligand Docking Method. Journal of Chemical Information and Modeling 2008, 
48, 1965-1973. 
52. Spassov, V. Z.; Yan, L.; Flook, P. K., The dominant role of side-chain backbone 
interactions in structural realization of amino acid code. ChiRotor: a side-chain prediction 
algorithm based on side-chain backbone interactions. Protein Sci 2007, 16, 494-506. 
53. Wu, G.; Robertson, D. H.; Brooks, C. L., 3rd; Vieth, M., Detailed analysis of 
grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD 
docking algorithm. J Comput Chem 2003, 24, 1549-1562. 
54. Davis, I. W.; Baker, D., RosettaLigand docking with full ligand and receptor 
flexibility. Journal of Molecular Biology 2009, 385, 381-392. 
55. Dunbrack, R. L., Jr.; Karplus, M., Backbone-dependent rotamer library for 
proteins. Application to side-chain prediction. Journal of Molecular Biology 1993, 230, 
543-574. 
56. Kolossavary, I.; Guida, W. C., Low-mode conformational search elucidated: 
Application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP. 
Journal of Computational Chemistry 1999, 20, 1671-1684. 
57. Kolossvary, I.; Keseru, G. M., Hessian-free low-mode conformational search for 
large-scale protein loop optimization: application to c-jun N-terminal kinase JNK3. J. 
Comput. Chem. 2000, 22, 21-30. 
58. Lexa, K. W.; Carlson, H. A., Protein flexibility in docking and surface mapping. 
Q. Rev. Biophys. 2012, 45, 301-343. 
59. Henzler, A. M.; Rarey, M., In Pursuit of Fully Flexible Protein-Ligand Docking: 
Modeling the Bilateral Mechanism of Binding. Mol. Inf. 2010, 29, 164-173. 
60. Sotriffer, C. A., Accounting for induced-fit effects in docking: what is possible 
and what is not? Curr Top Med Chem 2011, 11, 179-191. 
61. Agostino, M.; Jene, C.; Boyle, T.; Ramsland, P. A.; Yuriev, E., Molecular 
Docking of Carbohydrate Ligands to Antibodies: Structural Validation against Crystal 
Structures. J. Chem. Inf. Model. 2009, 49, 2749-2760. 
 97 
 
62. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J., Development and Testing of 
the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic 
Liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236. 
63. Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; 
Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D., Jr., CHARMM 
general force field: A force field for drug-like molecules compatible with the CHARMM 
all-atom additive biological force fields. J Comput Chem 2010, 31, 671-690. 
64. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A., 
Development and testing of a general Amber force field. J. Comput. Chem. 2004, 25, 
1157-1174. 
65. Gadakar, P. K.; Phukan, S.; Dattatreya, P.; Balaji, V. N., Pose Prediction 
Accuracy in Docking Studies and Enrichment of Actives in the Active Site of GSK-3β. J. 
Chem. Inf. Model. 2007, 47, 1446-1459. 
66. Celik, L.; Sinning, S.; Severinsen, K.; Hansen, C. G.; Moller, M. S.; Bols, M.; 
Wiborg, O.; Schiott, B., Binding of Serotonin to the Human Serotonin Transporter. 
Molecular Modeling and Experimental Validation. J. Am. Chem. Soc. 2008, 130, 3853-
3865. 
67. Liao, C.; Park, J.-E.; Bang, J. K.; Nicklaus, M. C.; Lee, K. S., Probing Binding 
Modes of Small Molecule Inhibitors to the Polo-Box Domain of Human Polo-like Kinase 
1. ACS Med. Chem. Lett. 2010, 1, 110-114. 
68. Felts, A. K.; LaBarge, K.; Bauman, J. D.; Patel, D. V.; Himmel, D. M.; Arnold, 
E.; Parniak, M. A.; Levy, R. M., Identification of Alternative Binding Sites for Inhibitors 
of HIV-1 Ribonuclease H Through Comparative Analysis of Virtual Enrichment Studies. 
J. Chem. Inf. Model. 2011, 51, 1986-1998. 
69. Babaoglu, K.; Shoichet, B. K., Deconstructing fragment-based inhibitor 
discovery. Nat. Chem. Biol. 2006, 2, 720-723. 
70. McRobb, F. M.; Capuano, B.; Crosby, I. T.; Chalmers, D. K.; Yuriev, E., 
Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled 
Receptors. J. Chem. Inf. Model. 2010, 50, 626-637. 
71. Barreca, M. L.; Iraci, N.; De Luca, L.; Chimirri, A., Induced-Fit Docking 
Approach Provides Insight into the Binding Mode and Mechanism of Action of HIV-1 
Integrase Inhibitors. ChemMedChem 2009, 4, 1446-1456. 
72. Sutton, M.; Atweh, G. F.; Cashman, T. D.; Davis, W. T., Resolving conflicts: 
misconceptions and myths in the care of the patient with sickle cell disease. Mt Sinai J 
Med 1999, 66, 282-285. 
 98 
 
73. Kotiah, S. D.; Ballas, S. K., Investigational drugs in sickle cell anemia. Expert 
Opin. Invest. Drugs 2009, 18, 1817-1828. 
74. Frenette, P. S.; Atweh, G. F., Sickle cell disease: old discoveries, new concepts, 
and future promise. J. Clin. Invest. 2007, 117, 850-858. 
75. Colombatti, R.; Maschietto, N.; Varotto, E.; Grison, A.; Grazzina, N.; 
Meneghello, L.; Teso, S.; Carli, M.; Milanesi, O.; Sainati, L., Pulmonary hypertension in 
sickle cell disease children under 10 years of age. Br. J. Haematol. 2010, 150, 601-609. 
76. de Franceschi, L.; Finco, G.; Vassanelli, A.; Zaia, B.; Ischia, S.; Corrocher, R., A 
pilot study on the efficacy of ketorolac plus tramadol infusion combined with 
erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle 
cell pain. Haematologica 2004, 89, 1389-1391. 
77. Tang, D. C.; Prauner, R.; Liu, W.; Kim, K.-H.; Hirsch, R. P.; Driscoll, M. C.; 
Rodgers, G. P., Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk 
of stroke in pediatric patients with sickle cell disease: A case-control study. Am. J. 
Hematol. 2001, 68, 164-169. 
78. Olowoyeye, A.; Okwundu Charles, I., Gene therapy for sickle cell disease. 
Cochrane Database Syst Rev 2010, CD007652. 
79. Steinberg, M. H.; Brugnara, C., Pathophysiological-based approaches to treatment 
of sickle cell disease. Annu. Rev. Med. 2003, 54, 89-112. 
80. Lou, T.-F.; Singh, M.; Mackie, A.; Li, W.; Pace Betty, S., Hydroxyurea generates 
nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp 
Biol Med (Maywood) 2009, 234, 1374-1382. 
81. Watson, J.; Stahman, A. W.; Bilello, F. P., The significance of the paucity of 
sickle cells in newborn negro infants. Am. J. Med. Sci. 1948, 215, 419-423. 
82. Michael Hall, A. N., Susan Smith, A foundation for neonatal care: a multi-
disciplinary guide. 1 ed.; Radcliffe Medical PR: 2009; p 258. 
83. Charache, S.; Terrin, M. L.; Moore, R. D.; Dover, G. J.; Barton, F. B.; Eckert, S. 
V.; McMahon, R. P.; Bonds, D. R., Effect of hydroxyurea on the frequency of painful 
crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in 
Sickle Cell Anemia. N Engl J Med 1995, 332, 1317-1322. 
84. Weiner, D. L.; Hibberd, P. L.; Betit, P.; Copper, A. B.; Botelho, C. A.; Brugunara, 
C., Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in 
pediatric patients with sickle cell disease. JAMA, J. Am. Med. Assoc. 2003, 289, 1136-
1142. 
 99 
 
85. Cokic, V. P.; Smith, R. D.; Beleslin-Cokic, B. B.; Njoroge, J. M.; Miller, J. L.; 
Gladwin, M. T.; Schechter, A. N., Hydroxyurea induces fetal hemoglobin by the nitric 
oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 2003, 111, 231-
239. 
86. Singh, H.; Dulhani, N.; Kumar, B. N.; Singh, P.; Tiwari, P., Effective control of 
sickle cell disease with hydroxyurea therapy. Indian J. Pharmacol. 2010, 42, 32-35. 
87. King, S. B., The nitric oxide producing reactions of hydroxyurea. Curr. Med. 
Chem. 2003, 10, 437-452. 
88. Huang, J.; Zou, Z.; Kim-Shapiro, D. B.; Ballas, S. K.; King, S. B., Hydroxyurea 
Analogues As Kinetic and Mechanistic Probes of the Nitric Oxide Producing Reactions 
of Hydroxyurea and Oxyhemoglobin. J. Med. Chem. 2003, 46, 3748-3753. 
89. Rohrman, B. A.; Mazziotti, D. A., Quantum Chemical Design of Hydroxyurea 
Derivatives for the Treatment of Sickle-Cell Anemia. J. Phys. Chem. B 2005, 109, 
13392-13396. 
90. King, S. B., N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and 
nitric oxide (NO) donors. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2005, 
5, 665-673. 
91. Lepeshkevich, S. V.; Parkhats, M. V.; Stepuro, I. I.; Dzhagarov, B. M., Molecular 
oxygen binding with α and β subunits within the R quaternary state of human hemoglobin 
in solutions and porous sol-gel matrices. Biochim. Biophys. Acta, Proteins Proteomics 
2009, 1794, 1823-1830. 
92. Safo, M. K.; Ahmed, M. H.; Ghatge, M. S.; Boyiri, T., Hemoglobin-ligand 
binding: Understanding Hb function and allostery on atomic level. Biochim. Biophys. 
Acta, Proteins Proteomics 2011, 1814, 797-809. 
93. Park, S.-Y.; Yokoyama, T.; Shibayama, N.; Shiro, Y.; Tame, J. R. H., 1.25 Å 
resolution crystal structures of human hemoglobin in the oxy, deoxy and carbonmonoxy 
forms. J. Mol. Biol. 2006, 360, 690-701. 
94. Yuan, Y.; Simplaceanu, V.; Ho, N. T.; Ho, C., An Investigation of the Distal 
Histidyl Hydrogen Bonds in Oxyhemoglobin: Effects of Temperature, pH, and Inositol 
Hexaphosphate. Biochemistry 2010, 49, 10606-10615. 
95. Kanias, T.; Acker, J. P., Biopreservation of red blood cells - the struggle with 
hemoglobin oxidation. Febs J. 2010, 277, 343-356. 
96. Bellelli, A., Hemoglobin and cooperativity: experiments and theories. Curr. 
Protein Pept. Sci. 2010, 11, 2-36. 
 100 
 
97. Yonetani, T.; Laberge, M., Protein dynamics explain the allosteric behaviors of 
hemoglobin. Biochim. Biophys. Acta, Proteins Proteomics 2008, 1784, 1146-1158. 
98. Dzhagarov, B. M.; Lepeshkevich, S. V., Kinetic studies of differences between α- 
and β-chains of human hemoglobin: an approach for determination of the chain affinity to 
oxygen. Chem. Phys. Lett. 2004, 390, 59-64. 
99. Umbreit, J., Methemoglobin-it's not just blue: a concise review. Am. J. Hematol. 
2007, 82, 134-144. 
100. King, S. B., C-Nitroso compounds, oximes, N-hydroxyguanidines and N-
hydroxyureas. Nitric Oxide Donors 2005, 177-199. 
101. Huang, J.; Hadimani, S. B.; Rupon, J. W.; Ballas, S. K.; Kim-Shapiro, D. B.; 
King, S. B., Iron Nitrosyl Hemoglobin Formation from the Reactions of Hemoglobin and 
Hydroxyurea. Biochemistry 2002, 41, 2466-2474. 
102. Pacelli, R.; Taira, J.; Cook, J. A.; Wink, D. A.; Krishna, M. C., Hydroxyurea 
reacts with heme proteins to generate nitric oxide. Lancet 1996, 347, 900. 
103. Konc, J.; Cesnik, T.; Konc, J. T.; Penca, M.; Janezic, D., ProBiS-Database: 
Precalculated Binding Site Similarities and Local Pairwise Alignments of PDB 
Structures. J. Chem. Inf. Model. 2012, 52, 604-612. 
104. Konc, J.; Janezic, D., ProBiS algorithm for detection of structurally similar 
protein binding sites by local structural alignment. Bioinformatics 2010, 26, 1160-1168. 
105. Konc, J.; Janezic, D., ProBiS: a web server for detection of structurally similar 
protein binding sites. Nucleic Acids Res. 2010, 38, W436-W440. 
106. Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.; 
McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.; 
Gibson, T. J.; Higgins, D. G., Clustal W and Clustal X version 2.0. Bioinformatics 2007, 
23, 2947-2948. 
107. Chen, H.; Ikeda-Saito, M.; Shaik, S., Nature of the Fe-O2 Bonding in Oxy-
Myoglobin: Effect of the Protein. J. Am. Chem. Soc. 2008, 130, 14778-14790. 
108. Park, S.-Y.; Yokoyama, T.; Shibayama, N.; Shiro, Y.; Tame Jeremy, R. H., 1.25 
A resolution crystal structures of human haemoglobin in the oxy, deoxy and 
carbonmonoxy forms. J Mol Biol 2006, 360, 690-701. 
109. Dodson, E.; Dodson, G., Movements at the hemoglobin A-hemes and their role in 
ligand binding, analyzed by X-ray crystallography. Biopolymers 2009, 91, 1056-1063. 
 101 
 
110. De Rosa, M. C.; Alinovi, C. C.; Russo, A.; Giardina, B., Binding modes of L35 to 
α- and β-semihemoglobins: Structural insights into the inequivalence of α- and β-subunits 
of hemoglobin. Biochem. Biophys. Res. Commun. 2007, 354, 720-726. 
111. Marechal, J.-D.; Maseras, F.; Lledos, A.; Mouawad, L.; Perahia, D., A DFT study 
on the relative affinity for oxygen of the α and β subunits of hemoglobin. J. Comput. 
Chem. 2006, 27, 1446-1453. 
112. Birukou, I.; Schweers, R. L.; Olson, J. S., Distal Histidine Stabilizes Bound O2 
and Acts as a Gate for Ligand Entry in Both Subunits of Adult Human Hemoglobin. J. 
Biol. Chem. 2010, 285, 8840-8854. 
113. Lukin, J. A.; Simplaceanu, V.; Zou, M.; Ho, N. T.; Ho, C., NMR reveals 
hydrogen bonds between oxygen and distal histidines in oxyhemoglobin. Proc. Natl. 
Acad. Sci. U. S. A. 2000, 97, 10354-10358. 
114. Suzuki, T.; Watanabe, Y.-H.; Nagasawa, M.; Matsuoka, A.; Shikama, K., Dual 
nature of the distal histidine residue in the autoxidation reaction of myoglobin and 
hemoglobin. Comparison of the H64 mutants. Eur. J. Biochem. 2000, 267, 6166-6174. 
115. Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.; 
Friesner, R. A., A hierarchical approach to all-atom protein loop prediction. Proteins 
Struct., Funct., Bioinf. 2004, 55, 351-367. 
116. Brooks, B. R.; Brooks, I. I. I. C. L.; Mackerell, J. A. D.; Nilsson, L.; Petrella, R. 
J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; 
Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, 
K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; 
Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. 
M.; Karplus, M., CHARMM: The Biomolecular Simulation Program. J. Comp. Chem. 
2009, 30, 1545-1614. 
117. Miller, B. T.; Singh, R. P.; Klauda, J. B.; Hodoscek, M.; Brooks, B. R.; 
Woodcock, H. L., III, CHARMMing: A New, Flexible Web Portal for CHARMM. J. 
Chem. Inf. Model. 2008, 48, 1920-1929. 
118. Misra, H. P.; Fridovich, I., Generation of superoxide radical during the 
autoxidation of hemoglobin. J. Biol. Chem. 1972, 247, 6960-6962. 
119. Konc, J. J., D., An Improved Branch and Bound Algorithm for the Maximum 
Clique Problem MATCH Commun. Math. Comput. Chem. 2007, 58, 569– 590. 
120. Simonneaux, G.; Bondon, A., Mechanism of electron transfer in heme proteins 
and models: The NMR approach. Chem. Rev. (Washington, DC, U. S.) 2005, 105, 2627-
2646. 
 102 
 
121. Kiger, L.; Marden, M. C., Electron transfer kinetics between hemoglobin 
subunits. J. Biol. Chem. 2001, 276, 47937-47943. 
122. Li, C.-z.; Liu, G.; Prabhulkar, S., Comparison of kinetics of hemoglobin electron 
transfer in solution and immobilized on electrode surface. Am. J. Biomed. Sci. 2009, 1, 
283-294. 
123. Huang, J.; Kim-Shapiro, D. B.; King, S. B., Catalase-Mediated Nitric Oxide 
Formation from Hydroxyurea. J. Med. Chem. 2004, 47, 3495-3501. 
124. Juul, T.; Malolepszy, A.; Dybkaer, K.; Kidmose, R.; Rasmussen, J. T.; Andersen, 
G. R.; Johnsen, H. E.; Jorgensen, J.-E.; Andersen, S. U., The in Vivo Toxicity of 
Hydroxyurea Depends on Its Direct Target Catalase. J. Biol. Chem. 2010, 285, 21411-
21415. 
125. Chiang, E. Y.; Frenette, P. S., Sickle cell vaso-occlusion. Hematol Oncol Clin 
North Am. 2005, 19, 771-784. 
126. Stuart, M. J.; Setty, B. N. Y., Sickle cell acute chest syndrome: pathogenesis and 
rationale for treatment. Blood 1999, 94, 1555-1560. 
127. Lanzkron, S.; Haywood, C., Jr.; Hassell, K. L.; Rand, C., Provider barriers to 
hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease 
Adult Provider Network. Journal of the National Medical Association 2008, 100, 968-
973. 
128. Strouse, J. J.; Lanzkron, S.; Beach, M. C.; Haywood, C.; Park, H.; Witkop, C.; 
Wilson, R. F.; Bass, E. B.; Segal, J. B., Hydroxyurea for sickle cell disease: a systematic 
review for efficacy and toxicity in children. Pediatrics 2008, 122, 1332-1342. 
129. Silva, D. G. H.; Belini, E., Jr.; Torres, L. d. S.; Ricci, O., Jr.; Lobo, C. d. C.; 
Bonini-Domingos, C. R.; Alves, d. A. E., Relationship between oxidative stress, 
glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell 
anemia. Blood Cells, Molecules, & Diseases 2011, 47, 23-28. 
130. King, S. B., Mechanisms and novel directions in the biological applications of 
nitric oxide donors. Free Radical Biology & Medicine 2004, 37, 735-736. 
131. Rupon, J. W.; Domingo, S. R.; Smith, S. V.; Gummadi, B. K.; Shields, H.; Ballas, 
S. K.; King, S. B.; Kim-Shapiro, D. B., The reactions of myoglobin, normal adult 
hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea. Biophysical Chemistry 
2000, 84, 1-11. 
132. Goyal, M. M.; Basak, A., Human catalase: looking for complete identity. Protein 
& Cell 2010, 1, 888-897. 
 103 
 
133. Fernandez-Lafuente, R., Stabilization of multimeric enzymes: Strategies to 
prevent subunit dissociation. Enzyme and Microbial Technology 2009, 45, 405-418. 
134. Wood, K. C.; Granger, D. N., Sickle cell disease: role of reactive oxygen and 
nitrogen metabolites. Clinical and Experimental Pharmacology and Physiology 2007, 34, 
926-932. 
135. Rovira, C.; Alfonso-Prieto, M.; Biarnes, X.; Carpena, X.; Fita, I.; Loewen, P. C., 
A first principles study of the binding of formic acid in catalase complementing high 
resolution X-ray structures. Chemical Physics 2006, 323, 129-137. 
136. Fita, I.; Rossmann, M. G., The active center of catalase. J Mol Biol 1985, 185, 21-
37. 
137. Alfonso-Prieto, M.; Biarnes, X.; Vidossich, P.; Rovira, C., The Molecular 
Mechanism of the Catalase Reaction. J. Am. Chem. Soc. 2009, 131, 11751-11761. 
138. Putnam, C. D.; Arvai, A. S.; Bourne, Y.; Tainer, J. A., Active and inhibited 
human catalase structures: Ligand and NADPH binding and catalytic mechanism. J Mol 
Biol 2000, 296, 295-309. 
139. Banks, J. L.; Beard, H. S.; Cao, Y.; Cho, A. E.; Damm, W.; Farid, R.; Felts, A. 
K.; Halgren, T. A.; Mainz, D. T.; Maple, J. R.; Murphy, R.; Philipp, D. M.; Repasky, M. 
P.; Zhang, L. Y.; Berne, B. J.; Friesner, R. A.; Gallicchio, E.; Levy, R. M., Integrated 
modeling program, applied chemical theory (IMPACT). Journal of Computational 
Chemistry 2005, 26, 1752-1780. 
140. Schr??dinger, L. L. C., LigPrep, version 2.3. 2009. 
141. Coutsias, E. A.; Seok, C.; Jacobson, M. P.; Dill, K. A., A kinematic view of loop 
closure. J. Comput. Chem. 2004, 25, 510-528. 
142. Gadakar, P. K.; Phukan, S.; Dattatreya, P.; Balaji, V. N., Pose Prediction 
Accuracy in Docking Studies and Enrichment of Actives in the Active Site of GSK-3Î? J 
Chem Inf Model 2007, 47, 1446-1459. 
143. Xiang, Z.; Honig, B., Extending the accuracy limits of prediction for side-chain 
conformations. J Mol Biol 2001, 311, 421-430. 
144. Brooks, B. R.; Brooks, C. L., III; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.; 
Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, 
Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; 
Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; 
Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. 
M.; Karplus, M., CHARMM: The biomolecular simulation program. J. Comput. Chem. 
2009, 30, 1545-1614. 
 104 
 
145. Woodcock, H. L., III; Hodoscek, M.; Gilbert, A. T. B.; Gill, P. M. W.; Schaefer, 
H. F., III; Brooks, B. R., Interfacing Q-chem and CHARMM to perform QM/MM 
reaction path calculations. Journal of Computational Chemistry 2007, 28, 1485-1502. 
146. Vankayala, S. L.; Hargis, J. C.; Woodcock, H. L., Unlocking the Binding and 
Reaction Mechanism of Hydroxyurea Substrates as Biological Nitric Oxide Donors. J 
Chem Inf Model 2012, 52, 1288-1297. 
147. McGann, P. T.; Ware, R. E., Hydroxyurea for sickle cell anemia: what have 
learned and what questions still remain? Current Opinion in Hematology 2011, 18, 158-
165. 
148. Karimi, M.; Zekavat, O. R.; Sharifzadeh, S.; Mosavizadeh, K., Clinical response 
of patients with sickle cell anemia to cromolyn sodium nasal spray. Am. J. Hematol. 
2006, 81, 809-816. 
149. Vrcek, I. V.; Sakic, D.; Vrcek, V.; Zipse, H.; Birus, M., Computational study of 
radicals derived from hydroxyurea and its methylated analogues. Organic & 
Biomolecular Chemistry 2012, 10, 1196-1206. 
150. Donzelli, S.; Espey, M. G.; Flores-Santana, W.; Switzer, C. H.; Yeh, G. C.; 
Huang, J.; Stuehr, D. J.; King, S. B.; Miranda, K. M.; Wink, D. A., Generation of nitroxyl 
by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine. 
Free Radical Biology & Medicine 2008, 45, 578-584. 
151. Alfonso-Prieto, M.; Vidossich, P.; Rovira, C., The reaction mechanisms of heme 
catalases: An atomistic view by ab initio molecular dynamics. Archives of Biochemistry 
and Biophysics 2012, 525, 121-130. 
152. Zipse, H., Radical stability - a theoretical perspective. Topics in Current 
Chemistry 2006, 263, 163-189. 
153. Pegg, A. E., Repair of O6-alkylguanine by alkyltransferases. Mutation Res. 2000, 
462, 83-100. 
154. Margison, G.; Povey, A. C.; Kaina, B.; Santibáñez-Koref, M. F., Variability and 
regulation of O
6
-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003, 24, 625-635. 
155. Tubbs, J. L.; Pegg, A. E.; Tainer, J. A., DNA binding, nucleotide flipping, and the 
helix-turn-helix motif in base repair by O
6
-alkylguanine-DNA alkyltransferase and its 
implications for cancer chemotherapy. DNA Repair (Amst) 2007, 6, 1100-1115. 
156. Gerson, S. L., MGMT: its role in cancer aetiology and cancer therapeutics. Nat. 
Rev. Cancer 2004, 4, 296-307. 
 105 
 
157. Pegg, A. E.; Dolan, M. E., Overcoming resistance to alkylating agents by 
inhibitors of O6-alkylguanine-DNA alkyltransferase. In DNA Repair in Cancer Therapy, 
Panasci, L. C.; Alaoui-Jamali, M., Eds. Humana Press, NJ: 2004; pp 143-177. 
158. Dolan, M. E.; Pegg, A. E., O6-Benzylguanine and its role in chemotherapy. 
Clinical Cancer Res. 1997, 3, 837-847. 
159. Middleton, M. R.; Margison, G. P., Improvement of chemotherapy efficacy by 
inactivation of a DNA-repair pathway. Lancet Oncol. 2003, 4, 37-44. 
160. Khan, O.; Middleton, M. R., The therapeutic potential of O
6
-alkylguanine DNA 
alkyltransferase inhibitors. Expert Opin. Investig. Drugs 2007, 16, 1573-1584. 
161. Dolan, M. E.; Moschel, R. C.; Pegg, A. E., Depletion of mammalian O
6
-
alkylguanine-DNA alkyltransferase activity by O
6
-benzylguanine provides a means to 
evaluate the role of this protein in protection against carcinogenic and therapeutic 
alkylating agents. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 5368-5372. 
162. Pegg, A. E.; Boosalis, M.; Samson, L.; Moschel, R. C.; Byers, T. L.; Swenn, K.; 
Dolan, M. E., Mechanism of inactivation of human O
6
-alkylguanine-DNA 
alkyltransferase by O
6
-benzylguanine. Biochemistry 1993, 32, 11998-12006. 
163. Daniels, D. S.; Mol, C. D.; Arvai, A. S.; Kanugula, S.; Pegg, A. E.; Tainer, J. A., 
Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical 
binding. DNA damage reversal revealed by mutants and structures of active and alkylated 
human AGT. Embo J. 2000, 19, 1719-1730. 
164. McElhinney, R. S.; Donnelly, D. J.; McCormick, J. E.; Kelly, J.; Watson, A. J.; 
Rafferty, J. A.; Elder, R. H.; Middleton, M. R.; Willington, M. A.; McMurry, T. B. H.; 
Margison, G. P., Inactivation of O6-alkylguanine-DNA alkyltransferase 1. Novel O6-
(hetarylmethyl)guanines having basic rings in the side chain. J. Med. Chem. 1998, 41, 
5265-5271. 
165. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. 
M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. 
E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; 
Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E., 2nd; Bigner, D. D.; 
Friedman, H. S., Phase I trial of temozolomide plus O
6
-benzylguanine for patients with 
recurrent or progressive malignant glioma. J. Clin. Oncol. 2005, 23, 7178-7187. 
166. Warren, K. E.; Aikin, A. A.; Libucha, M.; Widemann, B. C.; Fox, E.; Packer, R. 
J.; Balis, F. M., Phase I study of O
6
-benzylguanine and temozolomide administered daily 
for 5 days to pediatric patients with solid tumors. J. Clin. Oncol. 2005, 23, 7646-7653. 
 
 106 
 
167. Broniscer, A.; Gururangan, S.; MacDonald, T. J.; Goldman, S.; Packer, R. J.; 
Stewart, C. F.; Wallace, D.; Danks, M. K.; Friedman, H. S.; Poussaint, T. Y.; Kun, L. E.; 
Boyett, J. M.; Gajjar, A., Phase I trial of single-dose temozolomide and continuous 
administration of O
6
-benzylguanine in children with brain tumors: a pediatric brain tumor 
consortium report. Clin. Cancer Res. 2007, 13, 6712-6718. 
168. Batts, E. D.; Maisel, C.; Kane, D.; Liu, L.; Fu, P.; O'Brien, T.; Remick, S.; Bahlis, 
N.; Gerson, S. L., O
6
-Benzylguanine and BCNU in multiple myeloma: a phase II trial. 
Cancer Chemother. Pharmacol. 2007, 60, 415-421. 
169. Gajewski, T. F.; Sosman, J.; Gerson, S. L.; Liu, L.; Dolan, E.; Lin, S.; Vokes, E. 
E., Phase II trial of the O
6
-alkylguanine DNA alkyltransferase inhibitor O
6
-benzylguanine 
and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin. Cancer Res. 2005, 
11, 7861-7865. 
170. Ranson, M.; Middleton, M. R.; Bridgewater, J.; Lee, S. M.; Dawson, M.; Jowle, 
D.; Halbert, G.; Waller, S.; McGrath, H.; Gumbrell, L.; McElhinney, R. S.; Donnelly, D.; 
McMurry, T. B.; Margison, G. P., Lomeguatrib, a potent inhibitor of O
6
-alkylguanine-
DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and 
evaluation in combination with temozolomide in patients with advanced solid tumors. 
Clin. Cancer Res. 2006, 12, 1577-1584. 
171. Daniels, D. S.; Woo, T. T.; Luu, K. X.; Noll, D. M.; Clarke, N. D.; Pegg, A. E.; 
Tainer, J. A., Novel modes of DNA binding and nucleotide flipping by the human DNA 
repair protein AGT. Nat. Struct. Mol. Biol. 2004, 11, 714-720. 
172. Guengerich, F. P.; Fang, Q.; Liu, L.; Hachey, D. L.; Pegg, A. E., O
6
-
Alkylguanine-DNA alkyltransferase: Low pKa and reactivity of cysteine 145. 
Biochemistry 2003, 42, 10965-10970. 
173. Xu-Welliver, M.; Pegg, A. E., Point mutations at multiple sites including highly 
conserved amino acids maintain activity but render O6-alkylguanine-DNA 
alkyltransferase insensitive to O6-benzylguanine. Biochem J 2000, 347, 519-526. 
174. Pegg, A. E.; Xu-Welliver, M.; Loktionova, N. A., The DNA repair protein O
6
-
alkylguanine-DNA alkyltransferase as a target for cancer chemotherapy. In DNA 
alterations in cancer: genetic and epigenetic changes, M. Ehrlich, E., Ed. Eaton 
Publishing: Natick, MA, 2000; pp 471-488. 
175. Pegg, A. E.; Goodtzova, K.; Loktionova, N. A.; Kanugula, S.; Pauly, G. T.; 
Moschel, R. C., Inactivation of human O
6
-alkylguanine-DNA alkyltransferase by 
modified oligodeoxyribonucleotides containing O
6
-benzylguanine. J. Pharm. Exp. Ther. 
2001, 296, 958-965. 
 107 
 
176. Luu, K. X.; Kanugula, S.; Pegg, A. E.; Pauly, G. T.; Moschel, R. C., Repair of 
oligodeoxyribonucleotides by O
6
-alkylguanine-DNA alkyltransferase. Biochemistry 
2002, 41, 8689-8697. 
177. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, 
D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; 
Shenkin, P. S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method 
and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749. 
178. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, 
W. T.; Banks, J. L., Glide: a new approach for rapid, accurate docking and scoring. 2. 
Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759. 
179. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; 
Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T., Extra precision glide: docking and 
scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. 
Med. Chem. 2006, 49, 6177-6196. 
180. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; 
IShindyalov, I. N.; Bourne, P. E., The Protein Data Ban. Nucleic Acids Res. 2000, 28, 
235-242. 
181. Cho, A. E.; Guallar, V.; Berne, B.; Friesner, R. A., Importance of accurate 
charges in molecular mocking: quantum mechanical/molecular mechanical (QM/MM) 
approach. J. Comput. Chem. 2005, 26, 915-931. 
182. Bytheway, I.; Cochran, S., Validation of molecular docking calculations involving 
FGF-1 and FGF-2. J. Med. Chem. 2004, 47, 1683-1693. 
183. Goodtzova, K.; Crone, T.; Pegg, A. E., Activation of human O
6
-alkylguanine-
DNA alkyltransferase by DNA. Biochemistry 1994, 33, 8385-8390. 
184. Pegg, A. E.; Chung, L.; Moschel, R. C., Effect of DNA on the inactivation of O6-
alkylguanine-DNA alkyltransferase by 9-substituted O6-benzylguanine derivatives. 
Biochem. Pharmacol. 1997, 53, 1559-1564. 
185. Nelson, M. E.; Loktionova, N. A.; Pegg, A. E.; Moschel, R. C., 2-Amino-O
4
-
benzylpteridine derivatives: potent inactivators of O
6
-alkylguanine-DNA 
alkyltransferase. J. Med. Chem. 2004, 47, 3887-3891. 
 
 
 
 108 
 
 
 
Appendices 
 
Appendix A.  Supporting information and copyright permissions for chapter 2 
 
 
Figure A-1:  Generic  representation  of  second  lowest energy  pose  for  all  
hydroxyurea  analog IFD structures, 8 is shown as an example. 
 
A.1 Analysis of second low energy pose 
The significant hydrogen bonding contribution of HN'   leads us to examine the best 
binding pose of  hydroxyurea  analogs  in  OxyHb  that  involve  hydrogen  bonding  with 
HN'  to  residues other  than Gly25. This pose had hydrogen bonding to Od  for all analogs 
except 1 and 7. All IFD poses generated for 1 have hydrogen bonding to the OGly25. The 
generic representation of this pose is depicted in Figure A1. We  postulate  that  these  
 109 
 
orientations  will  not  be  highly  populated  since  the  hydroxyurea  analog radicals 
formed in reaction scheme 1 (Figure 7) cannot be stabilized in MetHb as the oxygen 
would be transformed into hydrogen peroxide and leaves the active site. The results also 
reveal that these binding poses have low favorable binding energies compared to the 
binding poses of HU analogs that has HN' hydrogen  bonded  to  OGly25. These  results  
convinced  us  that  the  second  pose  is  a  less  populated  low energy binding pose or 
may not even exist. 
 
Figure A-2: Image  retrieved  from  local  structure  similarity  profile  webpage  for  
Adult  Hemoglobin (HbA) protein (PDB/Chain ID: 2DN1/A). The heme is represented in 
stick model, conserved residues colored  red  in  CPK, and  the  protein  in  cartoon  
representation.   The  rainbow  colored  band  shows the structural similar of residues 
ranging from blue (variable) to red (structurally conserved). 
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Figure  A-3:  Mutiple  sequence  alignment  studies  of  human  globin  chains  includes 
α-Hb, δ-Hb, β-Hb, Cytoglobin,  Myoglobin  and  Human  Neuroglobin  using  ClustalW2  
in  which  2DN1-A  is  used  as  the query protein. Legends given below the sequences 
represent residues that are identical ("*"), observed conserved substitutions (":"), and 
observed semi-conserved substitutions ("."). The amino acid residues are  colored  
according  to  their  physiochemical  properties  in  which  red  implies  small  
hydrophobic (AFILMPVWY);  blue  implies  acidic  (DE);  purple  implies  basic  (HKR)  
and  green  implies  with hydroxyls and amines and basic too (CGHNQSTY) 
 
A.2 Sequence alignment studies 
Multiple sequence alignment  studies  were performed  using globin  sequences  
suggested  by  ProBiS. ClustalW2 was used to align selected proteins with the query 
sequence and visually inspect active site conserved residues (Figure A3). 
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Appendix B. Supporting information for catalase work 
 
Figure B-1: Predicted binding orientations of hydroxyurea analogs (3, and 4) pose 
conformations in catalase CpdI. 
 
 
Figure B-2: Modified analogs of 6 along with7 
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Figure B-3: Predicted binding orientations of hydroxyurea analogs (6a, and 6b) that gave 
pose A like conformations in catalase CpdI 
 
 
Figure B-4: Hydroxylamine reaction with catalase to produce HNO 
 
 
 
 
 114 
 
 
Figure B-5: Torsional angle Vs Energy plot 
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